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Implantable devices have the potential to solve current challenges in both 
physiological monitoring and drug delivery by introducing in situ measurement and 
treatment.  In this dissertation, two types of implantable devices will be discussed.  First, 
implantable devices for monitoring intraocular pressure (IOP) will be addressed.  Second, 
implantable devices made of both nonbiodegradable and biodegradable materials for 
bridging a peripheral nerve gap by in situ drug delivery will be discussed. 
Elevated IOP serves as a major factor that leads to glaucoma, a permanent vision 
loss disease, and a real-time monitoring implantable IOP sensor with 
polydimethylsiloxane membrane that was developed.  This IOP sensor can be either 
implanted in the lens capsular bag after cataract surgery or sandwiched between the sclera 
and the conjunctiva; the latter being more favorable due to easy signal retrieval.  For this 
approach, batch testing data showed a sensitivity of 0.67 mm/mmHg with the range of the 
device closely matching that expected for glaucoma patients.   
Another medical challenge addressed in this dissertation is that peripheral nerve 
gaps longer than 10mm require special bridging techniques to repair.  Autologous nerve 
grafts are the gold standard to repair peripheral nerve gaps; however, it possesses donor 
site deficit.  Hence, a drug delivery device consisting of a nerve conduit for guided axon 
growth is proposed, fabricated and verified in this dissertation.  Both nonbiodegradable 
materials and biodegradable materials were used to make the device that can deliver 
vascular growth factor, nerve growth factor (NGF), bovine serum albumin and 
polysaccharide.  Furthermore, a bioactivity test verified that the NGF released from the 
iv 
 
device was still bioactive in promoting axonal outgrowth on chick dorsal root ganglia 
explants.  Two 3-week pilot animal studies in mice and rats also showed that the device is 
biocompatible with no noticeable inflammatory response.  For the release kinetics, the 
device using diffusion through holes instead of a filter membrane had better consistency 
in release kinetics.  Two mathematical models were also developed to identify the 
optimal design of the nerve conduit and the model was verified by an in vitro release 
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 CHAPTER 1 
INTRODUCTION 
Implantable devices providing in situ monitoring and drug delivery can potentially 
answer current clinical needs in both ophthalmology and reconstructive surgery.  In this 
dissertation, an intraocular pressure (IOP) sensor using microfluidic concepts is presented 
and a discussion of the design, fabrication and characterization is provided.  Then, a 
nerve conduit made of either nonbiodegradable or biodegradable materials is proposed, 
manufactured and verified.    
Intraocular Pressure Sensors 
Glaucoma is the second leading cause of blindness in the United States, and its 
primary symptom is elevated IOP [1].  Normal IOP is near 10mmHg, whereas higher IOP 
between 23 to 35mmHg, can cause hypertension inside the eye and result in glaucoma 
and eventual damage to sensitive eye tissues, leading to blindness.   
Due to “white-coat compliance,” where patients consume a drug right before 
visiting an ophthalmologist to ensure their symptoms are minimal [2], [3], detection of 
lethal-pulse, high IOP is difficult.  Current IOP measurement uses a tonometer that 
measures cornea deflection caused by applied air-flow [4], giving the ophthalmologist an 
easy, relatively cheap way to estimate IOP.  However it lacks accuracy because of 
assumptions of a “normal” cornea stiffness, while cornea stiffness varies from patient to 
patient, and has no ability to detect the harmful IOP peak [5]–[7].  Different approaches 




none of them can provide accurate real-time IOP measurement.   
Several researchers have proposed tonometric-type devices for measuring IOP, 
though all still rely on consistent and known cornea properties for accuracy.  For example, 
Shaarawy et al. reported a wireless IOP monitoring system utilizing a disposable silicone 
contact lens to measure the change of the cornea curvature and transmit the signal 
through an antenna to an external device [12].  The change of cornea curvature due to 
changes in IOP [16] is one of the foundations for contemporary tonometers, and was 
utilized in this portable device to perform 24-hour IOP monitoring in which the sensor 
recorded the IOP value every 10 minutes.  Another approach by Sahel et al. reported a 
soft contact lens with an embedded resonant gauge to record the change of the cornea 
curvature [13].  They first simulated the functionality of the contact lens to determine the 
relationship between the curvature of the cornea to the IOP read-out value, then they 
placed the lens on porcine cadaver eyes with solution injected to adjust the input IOP 
value.  They also reported that the injection of fluids in the anterior chamber was better 
than in the posterior chamber because the former could produce small and constant IOP 
increases [13].  They showed that soft contact lenses could faithfully record the IOP value 
applied in the cadaver eyes.  A third effort in this area by M. Leonardi et al. discussed 
another soft contact lens made of polyimide that could record IOP values based on 
different cornea curvatures [14], [15].  For the first approach of the device, it was 
connected to an external power source through wires [14] and was not feasible for daily 
use.  Two pairs of “sensing-resistive strain gauges and compensation-resistive strain 
gauges” [15] were developed with a microprocessor transferring the curvature difference 




on the soft contact lens [15].  The fabrication process of this lens included microscale 
fabrication and cast molding.  It achieved a 109µV/mmHg sensitivity when tested in 
porcine cadaver eyes with applied fluids as pressure source [15].   
Though several methods have been proposed by Shaarawy, Sahel and Leonardi to 
improve contemporary Goldmann tonometer, they only changed the tonometer into a 
portable one so that it could perform 24-hour IOP monitoring.  This did not solve the 
problem that the cornea curvature cannot faithfully transmit IOP value due to varying 
stiffness in the cornea [5], [6].  Although these sensors might have good sensitivity with 
low error in a controlled experiment, their success for real IOP measurements in humans 
is unknown since the stiffness of the cornea cannot be modified before or after the 
experiment.  Thus, there remains a need for an accurate and inexpensive IOP 
measurement system.  Other groups also use tonometer as a sensing mechanism on 
contact lens-typed IOP sensors [13], [17], but the problem of different cornea stiffness is 
inevitable.   
Other types of IOP sensors that do not rely on cornea deflection have been 
proposed.  These implantable sensors provide real-time IOP monitoring, and the 
ophthalmologist or the patient can access the IOP reading.  Based on the sensing 
approach, these implantable sensors can be divided into three groups: capacitive pressure 
sensors, piezoresistive pressure sensors and unpowered pressure sensors.  
Capacitive pressure sensors, which are the most wide-spread pressure sensors, 
convert pressure-induced parallel plate displacement into a capacitance difference 
associated with a changing distance between or overlapping area of two or more parallel 




sensor and generates a corresponding pressure, the deformation of the plate will lead to 
shrinking of the distance between two or more parallel plates and therefore the 
capacitance of the parallel plates will increase.  On the other hand, if one plate shifts due 
to a shearing force while the other plate remains fixed, the overlapping area of the two 
parallel plates will decrease and therefore the capacitance will decrease.  Based on the 
direction of applied forces, the capacitance change can be detected by a custom integrated 
circuit.  Other groups also use capacitive difference to construct IOP sensors.  A group 
developed a capacitive IOP sensor with included antenna and showed a 1.6fF/mmHg 
sensitivity [20].   
Compared to piezoresistive pressure sensors, capacitance pressure sensors provide 
higher sensitivity, low noise and power consumption [21], and have been widely used for 
automatic, medically related household appliances and so forth for decades.  Several IOP 
examples have also been demonstrated. Wise et al. built intraocular pressure sensors, 
which converted contact area between the silicon diaphragm and the glass surface into 
capacitance change [22].  The sensing chamber in the sensor was under zero pressure. 
This was accomplished in the manufacturing process [23], and therefore “touch mode” 
was utilized to sense the applied pressure in absolute pressure reading between 550 to 
850mmHg [22] at which the applied pressure will lead to stacking of the silicon 
diaphragm on the electro plate [23].  This embedded IOP sensor consisted of an antenna, 
a glass chamber with a custom integrated circuit (ASIC), another glass chamber with a 
solar-powered microbattery, and a silicon sensing portion was designed to be attached to 
the iris [22], [24].  In sum, this device can automatically wake up, take an IOP 




transmit to the external receiver.  However, the size of the device is limited due to space 
available on the iris that does not either block the pupil or scratch the cornea [22], and 
hysteresis as well as low sensitivity were observed on this sensor [22].  
Another device proposed by P. Irazoqui et al. proposed a flexible IOP measurement 
device with a parylene-based capacitive IOP sensor, an integrated circuit (IC) and a 
nitinol antenna [25].  The device is flexible and small enough to be implanted in the 
anterior chamber of a mouse cadaver eye.  Two designs were characterized and showed a 
0.75fF/mmHg sensitivity in the dynamic range of 0-50mmHg relative to atmospheric 
pressure [25], as well as a resolution of less than 1mmHg. Because radio frequency (RF) 
is used to power the device, an imbedded battery is not required and this minimizes the 
dimension of the device [26]–[28].  However, both devices occupied the whole anterior 
chamber of the mouse cadaver eye, and thus light cannot go through the pupil and 
theoretically the mouse has no vision.  Nevertheless, P. Irazoqui et al. did not report if the 
device was suitable for implanting in human cadaver eyes.  The liquid crystal polymer 
substrate has no haptic to mount on the iris, and the device might move around in the 
anterior chamber of the human cadaver eye.  Several similar designs were developed and 
tested to be implanted in either porcine [26] or the Ansoft Human Body Model [29].  
They also implanted the device into mouse eyes and acquired a 1.5mHz/mmHg 
sensitivity [30].   
Piezoresistive pressure sensors are based on materials whose resistivity changes 
under an applied force because the distance between the conduction band and the valence 
band changes [31].  The gap, or the energy difference between the two bands, will affect 




piezoresistive pressure sensor consumes more power compared to capacitive pressure 
sensors [21], piezoresistive pressure sensors were still chosen by Ziaie et al. due to the 
low needed IOP measurement frequency.  Contemporary IOP measurement can only be 
accomplished while visiting the doctor’s office, and any improvement to this, for instance, 
measuring IOP twice a day, is better than the current technique.  Therefore, though the 
piezoresistive pressure sensor cannot perform IOP measurement every 15 minutes [22] 
like some of the other proposed sensors, it is still an improvement over the current 
tonometer-based IOP sensing technique.  Ziaie et al. reported several intraocular pressure 
monitoring systems utilizing the piezoresistive change of doped silicon to determine the 
applied pressure [32].  In these systems, implanted between the sclera and choroid, the 
sensing membrane registered the piezoresistive change and sent the measured change to 
an external device which converted the signals into pressure values.  They proposed two 
ways to mount the sensor on the eye.  Fixed IOP sensors were mounted on the eye by 
directly attaching them to a miniature positioning stage, and then sutured on the sclera 
[32].  These IOP sensors compared the IOP measured values with applied IOP values and 
generated calibration tables.  Though these devices were too big to function in vivo, they 
showed that sensing between the sclera and choroid was feasible and therefore this work 
will use this approach, as will be discussed later.  Another group also developed a 
piezoresistive IOP sensor, which used parylene as the substrate with a coating membrane 
and embedded circuits.  The complete sensor is rollable for easier implantation.  The 
measured sensitivity was 0.1mbar [33].   
Inductor based IOP sensors have also been proposed in which the vibration of two 




sensor with the sensing coil embedded in a SU-8 negative photoresist package can 
achieve a 3770ppm/mmHg in saline solution, with the resolution of less than 1mmHg 
[34].   
Unpowered pressure sensors use purely mechanical systems to monitor IOP change.  
Since they need no power supply, the volume and complexity of the sensor can be 
simplified, and the cost per sensor can be decreased dramatically.   
When air is injected in a hollow helix tube, it will tend to flatten the tube due to 
difference in bending moment on the two sides of the tube, and thus the tip of the tube 
will rotate and the curvature of the tube will increase [35], [36].  This tube is known as 
Bourdon tube, proposed in the 18th Century.  
Tai et al. reported three kinds of unpowered parylene-based IOP sensors with 
different Bourdon tube designs [36]–[40].  A customized 19 gauge needle was used to 
carry the sensor and penetrate through the cornea.  The incision was less than 3mm and 
therefore suturing after surgery was not required [36], [41].  The sensor was placed on the 
iris due for both ease of optical readout and appropriate pressure sensing [37].  Mounting 
tests were performed on the iris of rabbit eyes to demonstrate that secure placement was 
achieved.  Parylene posts were used to secure the device on the iris [37].  IOP reading 
tests were performed in vitro and ex vitro with designs developed to amplify the readout 
and increase the sensitivity.  These Bourdon-tube IOP sensors had a sensitivity of 
0.67degree/mmHg, 3.43µm/mmHg and 0.38µm/mmHg in different designs.  Although 
this approach has an advantage of simplifying the design, it has the potential to block 
incoming light through the pupil at night since this device occupied lots of space on the 




signal transmission mechanism, signal transmission material and energy source were 
shown in Table 1.   
Table 2 shows a comparison of different sensors in sensitivity, resolution, location 
of the sensor and dynamic range.   
The various capacitive pressure sensors, piezoresistive pressure sensors and 
Bourdon-tubed IOP sensors that have been proposed all addressed some concerns 
regarding IOP measurement, but none were ideal or resolved all of the existing concerns 
with commercially available tonometers.  Thus, we propose to continue development in 
this area and propose an unpowered IOP sensor designed to solve contemporary IOP 
monitor issues. 
The goal of the IOP sensor proposed in this dissertation is to estimate actual IOP 
value without measuring the cornea deflection, which is a known issue leading to 
inaccurate IOP estimates.   
Nerve Conduits for Peripheral Nerve Regeneration 
Introduction to Socioeconomic Effects 
Three hundred and sixty thousand people in United States and 300,000 in Europe 
suffer from upper extremity paralytic syndromes each year [42].  More than 200,000 
nerve repair procedures are performed each year in the United States [43].  Many workers 
miss days due to the loss of motor or sensory functions of extremities [44].  In addition to 
acute nerve injury, chronic neuropathic pain can affect patients’ quality of life and lead to 
a variety of effects including sleep interruption  [45], [46].   
Peripheral nerve injuries also affect 2.8% of trauma patients [49] and significantly 




Table 1 Comparison of different sensors in: sensing mechanism, sensing material, signal 
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Table 2 Comparison of different sensors in: sensitivity, resolution, location of the sensor 
and dynamic range 







On the iris of a 
human cadaver 










0.76fF/mmHg for the 
initial device with poor 
resolution [25], [27].  
0.3fF/mmHg for the 
next device with better 












chamber of a 
mouse cadaver 
eye 
0-50mmHg [25];  
0-60mmHg [27] 
[26] Not reported Not 
reported 
Porcine eye Not reported 
[29] 6.64fF/mmHg [29] 0.5mmHg 
[29] 
Anterior 
chamber of an 
Ansoft Human 




8.72µm/mmHg in ex 
vivo sample [36]. 
0.67degree/mmHg for 
spiral design [40]. 
3.43µm/mmHg for 





for in vitro 
sample 
[36] 
Mount on the 
iris [36] 
29-88mmHg for 




0.061mm/mmHg for the 
dynamic range between 
0-22mmHg; 
0.667mm/mmHg for the 


























Table 2 (continued) 
Group Sensitivity Resolution Location of 
the Sensor 
Dynamic Range 
[12] Not reported Not 
reported 
Outside of 
















109µV/mmHg [15] 1mmHg 
[15] 
Outside of 









sensory and pain functions [50] with contemporary treatments [45], spurring research into 
alternative methods to address this clinical need.   
Clinical Rationale 
Based on Sunderland Classification [51], nerve damage can be classified into five 
grades: neuropraxia, axonotmesis, neurotmesis with preservation of the perineurium, 
neurotmesis with preservation of the epineurium, and complete transaction of the nerve 
trunk [52].  Most of the Grade 1 (neuropraxia) patients can fully recover without any 
surgery since only some blockage of electrical and chemical signals in axon transmission 
occurs in this stage, and no mechanical or physical break of the nerve has occurred.  For 
Grade 2, since only the integrity of the axon is broken, with proper treatment (e.g., 
providing nerve growth factor), repair will by itself because the endoneurium will guide 
the axon to grow properly.  However, in Grades 3-5, due to the fact that the nerve is 
actually cut, or even a particular part is missing in the worst case scenario, physical 
bridging is required to guide the axon to grow to the distal site on the patient.   
About 87.4% of upper limb nerve injuries could be repaired by end-to-end 
approximation, while 1.8% of upper limb nerve injuries require grafts or another form of 
bridge to connect the two nerve stumps [53].  End-to-end tension-free severed nerve re-
approximation is performed for peripheral nerve gaps less than 10mm, while special 
bridging techniques are required for gaps larger than 1-2cm [52].  For those requiring 
bridging techniques, nerve autografts are the gold standard, but still have some 
limitations, such as donor site deficits or morbidity [54], [55], possible disease spread and 
secondary deformity [56].  Thus, there is significant need for methods of nerve repair that 




similar functional outcomes for regeneration [57], research has been conducted using a 
nerve conduit to repair the peripheral nerve gap due to its more flexible selection [58].  
Several options have emerged to improve outcomes in repairing peripheral nerve gaps.  
These include artificial nerve grafts, cadaver grafts and nerve conduits.  Nerve conduits 
made with either natural or synthetic materials have been used to guide axons and bridge 
nerve gaps ranging from 5 to 80mm [59].  Design and outcome of various kinds of nerve 
conduits will be discussed in the following sections.   
Various Nerve Conduits and Their Outcome 
Autologous grafts (autografts) are the gold standard for repairing peripheral nerve 
gaps greater than 10mm.  Currently, nerves with less important functions are used to 
serve as autografts, such as superficial nerves, sural nerves and lateral antebrachii 
cutaneous nerves [60].  However, autografts have the drawbacks of donor site deficits in 
which not only is a proper donor nerve hard to find for particular clinical application, but 
a significant risk of forming a neuroma in the donor site is expected [60].  Therefore, 
various studies have been proposed and conducted in order to build a nerve conduit to 
replace an autograft in repairing peripheral nerve gaps of more than 10mm.  These 
materials include natural and synthetic materials, which will be discussed in the following 
paragraphs.  The materials to form the nerve conduits can be either collagen, polyaniline 
(PANI), polyglycolic acid (PGA), poly 2-hydroxyethyl methacrylate methyl methacrylate 
(PHEMA-MMA), polylactide co-caprolactone (PLCL), polylacticcoglycolic acid (PLGA), 
poly l-lactic acid (PLLA), polyphosphoeaster (PPE), polypyrrole (PPY) or polyurethane 
(PU).  Table 3 shows a comparison of different nerve conduits in material, drug, result, 




Table 3 Comparison of different nerve conduits in: material, drugs, results, animals and 
targets 
Reference Material Drug Result Animal/target 
[61] Collagen GDNF & 
NGF 
Both GDNF and NGF 
were bioactive after 30 
days of release study 
Chick/ dorsal root 
ganglia explants. 
[58] Collagen n/a Both the 
electrophysiological and 
histomorphometry showed 
a similar outcome for the 
autograft or the collagen 
repaired groups. 
Monkey/ ulnar or 
median nerve. 




inspection, and a 




Collagen The group bridged with 
PLGA-coated collagen 
tubes filled with collagen 
gel had better outcomes in 
both electophysiology and 
morphology compared 
with another group 
bridged with collagen-
filled vein grafts. 
Rabbit/ peroneal 
nerve. 
Gap size of 15mm. 
Experimental 
period: 12 weeks. 







The group bridged with 
the supply of magnetically 
aligned collagen gel 
showed superior outcomes 
in distal axon density after 
30 days post surgery 
compared to the group 
with either the supply of 
control collagen gel or 
without supply in repairing 
both 4mm and 6mm gaps. 
Mouse/ sciatic 
nerve.  
Gap size of 4mm or 
6mm.  
Experimental 











Five months after the 
implantation, presence of 
myelinated, unmyelinated 
axons and Schwann cells 
was confirmed. 
Electrophysiology also 
showed a recovery of 
sensory function 5 months 
after the implantation. 
Cat/ sciatic nerve. 








Table 3 (continued) 







Walking track analysis 
showed a similar result for 
the group bridged with 
PGA-collagen tube 
compared to the normal 
uninjured group.  
Histology showed a 
relatively high quantity of 




Gap size of 80mm. 
Experimental 









collagen tube could 
achieve a similar result in 
electrophysiology and 
histomorphometry 
compared with autograft, 
and had a superior result 
over empty collagen or 
silicone tubes in axon size 
and quantity.  
Rat/ sciatic nerve. 
Gap size of 10mm. 
Experimental 
period: 60 weeks. 
[67] (solid bar) 
collagen 
n/a The number of myelinated 
axons at the distal nerve 
stump was bigger when 
bridged with collagen 
filaments compared to 
autografts. 
Rat/ sciatic nerve.  
Gap size of 20mm.  
Experimental 




n/a Sixty percent of the group 
repaired with PHEMA-
MMA hydrogel conduits 
showed similar results in 
electrophysiological 
response compared with 
the group treated with 
autografts. 
Rat/ sciatic nerve. 







Table 3 (continued) 






















The conduit with higher 
dosage of acidic fibroblast 
growth factor could 
produce the best result in 
fiber density in the 
conduit, and this result 
was similar to the group 
repaired with autografts. 
Rat/ sciatic nerve. 











conduit with fibroblast 
growth factor-1 coating 
showed similar results in 
both electrophysiology and 
histomorphometry 
compared to autograft 
Rat/ sciatic nerve.  
Gap size of 10mm.  
Experiment period: 




NGF NGF-loaded microspheres 
or NGF-incorporated 
channel could deliver NGF 
constantly in the 28-day 
period compared to the 
NGF-imbibed channel 
No animal model.   
[72] PGA n/a The PGA-bridged group 
showed better functional 
recovery compared to end-
to-end reapproximation 
(for gaps less than 4mm) 
or autografts (for gaps 
greater than 8mm) 
Human/ digital 
nerves. 
Gap size of either 
less than 4mm or 
greater than 8mm.  
Experiment period: 





Table 3 (continued) 
Reference Material Drug Result Animal/target 
[73] PLCL n/a The PLCL-bridged group 
showed a similar axonal 
regrowth in length 
compared to autografts.  It 
also showed a similar 
sensory recovery 
compared to the group 
bridged with autografts. 
Human/ digital 
nerves. Gap size of 
lesser than 20mm.   
Experiment period: 
12 months.  
[74], [75] PLLA Schwann 
cells 
PLLA conduits coated 
with Schwann cells 
showed better outcomes in 
both 2-month 
gastrocnemius muscle loss 
comparison and 4-month 
axon density test at distal 
nerve stumps.   
Rat/ sciatic nerve. 
Gap size: 12mm. 
Experiment period: 
4 months. 
[76] PPE n/a PPE conduits with higher 
molecular weight had 
better outcome in the 
reflex test on the repaired 
sciatic nerve. 
Rat/ sciatic nerve. 











NGF The group with NGF-
encapsulated PPE 
microsphere had better 
ratio for axonal regrowth 
(4 out of 6 works) 
compared to the NGF-only 
group (3 out of 6 works) 
and empty group (none 
works). 
Rat/ sciatic nerve. 











NGF The NGF-loaded PPE 
microsphere had better 
outcomes over the control 
groups in morphological 
analysis of fiber diameter, 
fiber population and fiber 
density 
Rat/ sciatic nerve. 







Table 3 (continued) 






GGF-only foam conduit 
had higher axon numbers 
compared to the one with 
both GGF and Schwann 
cells.  The foam conduit 
with both GGF and 
Schwann cells had higher 
myelination index and 
fastest conduction velocity 
compared with the GGF-
only group.   
Rat/ sciatic nerve. 







The PLGA foam conduit 
with Schwann cells had a 
denser axon distribution at 
the middle of the gap 
compared to the one 
bridged with autografts. 
Rat/ sciatic nerve. 







In histology, the group 
bridged with Pluronic 
F127-coated PLGA 
conduits showed a faster 
(4 weeks earlier) physical 
recovery compared to the 
group bridge with empty 
PLGA conduits or empty 
silicone conduits.   
In electrophysiological 
testing, the group with 
Pluronic F127-coated 
PLGA conduit transmitted 
the signal faster compared 
to the other two groups 
after 24 weeks  
Rat/ sciatic nerve. 





n/a These empty PLGA 
conduits could promote 
peripheral nerve 
regeneration in rats. 
Rat/ sciatic nerve.  







Table 3 (continued) 
Reference Material Drug Result Animal/target 
[83] PU n/a At 4-week postoperation, 
functional recovery was 
achieved in both walking 
track analysis and 
electrical stimulation.  
Histology data also show 
that axons are denser at 
distal nerve stump after 8 
weeks of repair compared 
to the one after 4 weeks. 
Rabbit/ femoral 
nerve.  





n/a The group treated with 
collagen-PU bilayer 
conduit had better 
outcome in histology, 
walking track analysis and 
electrophysiological tests 




Gap size of 10mm. 
Experiment period: 
6 weeks. 
[85] PU ACTH4-9 
NGF 
The group treated with 
NGF-loaded PU conduits 
had a similar result in 
electrical stimulation test 
compared with the one 
treated with autograft.  The 
group with NGF-loaded 
PU conduits showed 
denser axon compared to 
the group with autograft. 
Rat/ sciatic nerve.  









An environment that more successfully mimics a biologic environment can be 
generated by natural materials due to the extracellular matrix that will create a cell-
adhesive surface to possibly reduce foreign body response and fibrosis [59].   
Collagen 
Due to the fact that collagen is a key element in the extracellular matrix, collagen is 
suitable for forming the nerve conduits for repairing peripheral nerve gaps.  One study 
showed that collagen tubes can store and deliver both glial cell line-derived neurotrophic 
factor (GDNF) and nerve growth factor (NGF) for a 30-day period, and the bioactivity of 
both GDNF and NGF was verified with chick DRG cells [61].  Another study showed 
that empty collagen conduits can achieve similar results in both histomorphometry and 
electrophysiology studies to repair 5 to 15mm gaps on monkey ulnar or median nerves 
compared to the autograft group [58].  Another study created a 15mm gap on the peroneal 
nerve of rabbits and showed that PLGA-coated collagen conduits filled with collagen gel 
can achieve better electrophysiological and morphological outcomes compared to the 
group bridged with collagen-filled vein grafts [62].  Another study used a different design 
of collagen tubes to bridge either a 4mm or a 6mm gap on mouse sciatic nerves, and it 
showed that the group with the supply of magnetically aligned collagen gel has superior 
outcomes in distal axon density 30 days post surgery compared to the groups with either 
the supply of control collagen gel or without supply in repairing both 4mm and 6mm 
gaps[63].  Another study focused on repairing a long gap distance by first repairing a 
25mm gap on cat sciatic nerves with a PGA-collagen conduit filled with laminin-




after the implantation, they confirmed the presence of myelinated, unmyelinated axons 
and Schwann cells [64].  Electrophysiology also showed a recovery of sensory function at 
5 months after the implantation.  In a subsequent study, these researchers used a PGA-
collagen conduit filled with laminin-soaked collagen sponge to bridge an 80mm gap 
created on dog peroneal nerve for 12 months.  Walking track analysis revealed a similar 
result to the normal uninjured dog, though histology shows a relatively high quantity of 
immature axons at the distal nerve stump 12 months post surgery [65].  Another study 
compared empty collagen tubes, empty silicone tubes, autografts and collagen-
glycosaminoglycan-filled collagen tubes to bridge 10mm gaps on rat sciatic nerves for 60 
weeks and showed that the group with the supply of collagen-glycosaminoglycan matrix 
in a collagen tube has the superior outcome in axon size and quantity compared to the 
other groups bridged with either empty collagen or silicone tubes. The histomorphometric 
and electrophysiological results of the group bridged with collagen-glycosaminoglycan-
filled collagen tubes are similar to the group bridged with autograft [66].  Yet another 
sutdy used collagen as a solid bridge to repair a 20mm gap created on rat sciatic nerves 
for 8 weeks.  It showed that the number of myelinated axons at the distal nerve stump is 
greater compared to the group bridged with autografts after 8 weeks [67].   
Synthetic Materials 
An advantage of synthetic materials is that a custom property (e.g., degradation rate) 
and structure are relatively easy to acquire compared to natural materials.  In addition, a 






A study showed that electric stimulation from conductive polymers such as PPY 
and PANI could promote local nerve regeneration by stimulating neurite outgrowth [86].   
Hydrogel 
A 16-week study used PHEMA-MMA to form 12mm long hydrogel conduits for 
repairing 10mm nerve gaps created on rat sciatic nerves [68].  It showed that 60% of the 
group repaired with PHEMA-MMA hydrogel conduits had similar results in 
electrophysiological response compared to the group bridged with autografts.  Prior to 
this study, a preliminary study conducted by the same group showed that the PHEMA-
MMA conduit would cause some chronic inflammation when repairing 10mm gaps on rat 
sciatic nerves [87], and this research group indicated that a further study would be 
conducted to increase the biocompatibility of the conduit.  Another study filled a 12mm 
long PHEMA-MMA hydrogel conduit with either collagen matrix, collagen with 
neurotropin-3, collagen with brain-derived neurotrophic factor, or collagen with acidic 
fibroblast growth factor to bridge 10mm nerve gaps on rat sciatic nerves for 8 weeks [69].  
It showed that the conduit with higher dosage of acidic fibroblast growth factor could 
lead to the best result in fiber density inside the conduit, which was similar to the group 
repaired with autografts.  Another study showed that a coil-reinforced PHEMA-MMA 
hydrogel conduit with fibroblast growth factor-1 coating could achieve similar results in 
electrophysiology and histomorphometry compared to autograft when bridging a 10mm 
gap on rat sciatic nerve for 16 weeks [70].  Another study compared three ways to 
incorporate NGF into a PHEMA-MMA hydrogel channel and found that NGF-loaded 




period compared to the NGF-imbibed channel [71], but no animal data were available for 
this study.   
Polyglycolic Acid (PGA) 
A study used a PGA conduit without a supply of drug to repair human digital nerve 
gaps (n=120) from less than 4mm or greater than 8mm and showed a better sensory 
recovery compared to end-to-end re-approximation (for gaps less than 4mm) or autografts 
(for gaps greater than 8mm) [72].   
Polylactide Co-caprolactone (PLCL) 
A study showed that a PLCL conduit without the supply of drug was able to 
achieve similar axonal regrowth and sensory recovery for human hand nerves (n=30) for 
a 12-month period compared to autografts [73].   
Poly L-lactic Acid (PLLA) 
A study compared the results for Schwann cell-coated PLLA conduits with empty 
silicone conduits, isografts and collagen-filled PLLA conduits to bridge a 12mm gap on 
rat sciatic nerves.  For gastrocnemius muscle loss comparison, the PLLA conduits coated 
with Schwann cells showed a superior result compared to the other groups 2 months after 
the implantation. It also showed that a higher density of axons was found at the distal 
nerve stump in the group treated with Schwann cell-coated PLLA conduits 4 months after 
the implantation [74], [75].   
Polylactic Co-glycolic Acid (PLGA) 
A study showed that PLGA nerve conduits with the supply of glial growth factor 




axonal outgrowth through a 10mm gap, and the GGF-only group had denser axon, while 
the combination of GGF and Schwann resulted in higher myelination index and faster 
conduction velocity [79].  Another study showed an 85/15 PLGA foam conduit with 
diameter from 60 to 550 µm coated with Schwann cell could bridge a 7mm sciatic nerve 
gap on rat models for 6 weeks, with a higher axon density in the middle of the gap 
compared to the group treated with autografts [80].  Another study also showed that 
PLGA pellets could deliver recombinant human NGF (rhNGF) consistently in a 14-day 
diffusion chamber study [88], and the NGF was released from the PLGA microspheres 
through hydrolysis of PLGA [89].  Another study using Pluronic F127-coated 75/25 
PLGA conduits showed that a faster recovery rate (4 weeks versus 8 weeks in repairing a 
10mm gap on rat sciatic nerves) was found compared to empty PLGA conduits.  It also 
showed that a faster electrophysiological signal transmission was found in the group 
treated with Pluronic F127-coated PLGA conduits compared to the group with empty 
PLGA conduits at 24 weeks postimplantation [81].  The other study showed even an 
empty 90/10 PLGA conduit was able to promote peripheral nerve regeneration on a 
12mm gap on rat sciatic nerves in a 9-week period [82].   
Polyphosphoester (PPE) 
PPE shows a better hydrolysis degradability because the phosphoester linkage is 
easier to cleave compared to the ester linkage in PLGA [59].  A study implanted two 
groups of empty PPE conduits with different molecular weight (15kDa and 19kDa) in rats 
(n=12) to bridge a 10mm gap created on sciatic nerves for a period of 3 months.  It 
showed that the conduit with higher molecular weight had better outcomes in reflex test 




PPE microspheres suspended in saline, NGF dissolved in saline and empty silicone 
conduit to bridge 10mm gaps in rat sciatic nerves for 2 weeks.  It shows that the group 
with NGF-encapsulated PPE microspheres had better chances to promote axonal 
regrowth to the distal nerve stump (4 out of 6 worked) compared to the NGF-only group 
(3 out of 6 worked) and empty conduit group (0 worked) [77].  Therefore, they filled PPE 
conduits with these NGF-loaded PPE microspheres and started another 3 months 
implantation study to bridge 10mm gaps on rat sciatic nerves.  It showed better outcomes 
in morphological analysis of fiber density, diameter and population compared to the 
control groups [78].   
Polyurethane (PU) 
PU has been used to construct nerve conduits because of its flexibility, which can 
be an advantage in some implantation places that require frequent motion.  A study used 
20mm nerve conduits made of PU to repair 12mm gaps on rabbit femoral nerve for a 
period of 6 months [83].  It showed that these drug-free conduits could result in 
functional recovery in both walking track analysis and electrical stimulation at 4-week 
postoperation.  It also showed that at 8-week postoperation, the axon at the distal nerve 
stump was denser compared to the one at 4-week postoperation.  The same researchers 
later embedded a collagen tube into the PU nerve conduit in order to allow better nutrient 
transportation in the nerve conduit.  This study used this bilayer PU-collagen nerve 
conduit to bridge a 10mm gap created on rat sciatic nerve for a period of 6 weeks.  The 
group with bilayer conduit had a better result in histology, walking track analysis and 
electrophysiological tests compared to the PU-only conduits [84].  Another study also 




repair an 8mm gap on rat sciatic nerve for a period of 16 weeks.  It showed that the PU 
nerve conduit could achieve a similar result in electrical stimulation test compared with 
the group treated with autograft.  It also showed that axons were denser at the proximal 
nerve stump in the group treated with these PU nerve conduits compared to the group 
treated with autografts [85].  The other study used polyester urethane nerve conduit to 
repair an 8mm gap created on rat sciatic nerve for 24 weeks for a preliminary degradation 
study and showed that the nerve conduit could degrade four weeks post implantation [90].   
Innovation of the Nerve Conduit Proposed in This Study 
Due to the fact that empty nerve conduits can achieve comparable results to 
autografts when the gap size is smaller than 5cm in humans, or 1.5cm in rats [59], nerve 
conduits will provide a starting point and then be filled with protein or drug to stimulate 
axonal regrowth.  The combination of drug delivery and physical nerve guidance is 
hypothesized to lead to better nerve regeneration outcomes.   
Though some tissue-engineered conduits provide results comparable or superior to 
autologous grafts [91], [92], it is difficult to switch the neurotrophin or protein in the 
device to fit different target nerve gaps.  In addition, the use of various drug delivery 
mechanisms, such as microspheres, coatings, collagen sponges or filling with 
neurotrophin solution in the lumen of singe conduits, suffers from a lack of flexibility in 
choosing various drugs and drug concentrations when used with different types of 
peripheral nerve repair surgery.  Thus, a device that is easily customizable in both 
dimensions and drugs (growth factors) of interest is proposed in this paper.  NGF was 
chosen as the drug delivered in the project because not only are there fewer adverse 




growth [57], but also because denser axon branches are observed in chick DRG cells 
when treated with NGF over GDNF [93], [94].  Research has shown that locally 
delivered NGF can accelerate sciatic nerve regeneration [95]–[97].   
The work included in this dissertation proposes a new, easily tailored approach to 
delivering drugs to treat peripheral nerve gaps.  The general concept is to create a nerve 
guidance conduit surrounded by a drug reservoir that delivers drug into the lumen of the 
conduit, thereby encourage rapid, directed nerve growth.  Switching drugs should be 
straightforward as the kinetics of release can readily be modeled and calculated, in 
comparison to techniques that require material degradation.  This work focuses on a 
PDMS device that implements the critical functions of the proposed device, followed by 
a biodegradable PLGA device in a more advanced study with in vivo data.   
The advantage and biocompatibility of polydimethylsiloxane (PDMS) have been 
addressed in the previous section of this dissertation to form an IOP sensor.  PDMS with 
the same recipe will be used to form the prototypes of the concentric nerve conduits, with 
bovine serum albumin (BSA), vascular endothelial growth factor (VEGF), nerve growth 
factor (NGF) and Dextran used as the drug or test molecule of interest to reveal the 
release function of the device.   
After testing prototypes made of PDMS, PLGA with a 75/25 PLA/PGA copolymer 
ratio was chosen to form the biodegradable nerve conduit discussed in this dissertation 
due to its moderate degradation time compared to 50/50 or 85/15 PLGA polymers.  75/25 
PLGA has a half life about 20 days, which is longer compared to 65/35 PLGA due to the 
methyl group in PLA impeding the reaction between water and PLGA [98], reducing the 




Combining the advantage of the synthetic nerve conduit’s flexible design and 
NGF’s effect on nerve growth, several types of nerve conduits will be designed, 
fabricated and verified in vitro, ex vivo and in vivo in this dissertation.   
Dissertation Overview 
Chapter 2 of this dissertation will discuss a project to design, fabricate, verify and 
characterize several IOP sensors.  Chapter 3 of this dissertation will explain a PDMS 
nerve conduit loaded with either NGF or Dextran for peripheral nerve regeneration.  
Chapter 4 of this dissertation will describe a PLGA nerve conduit loaded with NGF for 
peripheral nerve regeneration with in vitro and ex vivo verification data.  Chapter 5 of this 
dissertation will provide all supplementary data for both PDMS and PLGA nerve 
conduits loaded with either VEGF, BSA, Dextran or NGF for in vitro release study or in 
vivo animal study.  This chapter will also describe the model for predicting local NGF 
concentration at the proximal nerve stump.  Chapter 6 will conclude the whole 
dissertation by summarizing the contributions of the author and future work.   
 CHAPTER 2 
INTRAOCULAR PRESSURE SENSORS: NEW APPROACHES FOR REAL-TIME 
INTRAOCULAR PRESSURE MEASUREMENT USING  
A PURELY MICROFLUIDIC CHIP 
Introduction 
Glaucoma and Contemporary Intraocular Pressure Measurement 
Glaucoma is the second leading cause of blindness in the United States, and its 
primary symptom is elevated intraocular pressure (IOP) [1].  Normal IOP is near 
10mmHg, whereas higher IOP, between 23 to 35mmHg, can cause hypertension inside 
the eye and result in glaucoma and eventual damage to sensitive eye tissues, leading to 
blindness.   
Due to “white-coat compliance,” where patients consume a drug right before 
visiting an ophthalmologist to ensure their symptoms are minimal [2], [3], detection of 
lethal-pulse, high IOP is difficult.  Current IOP measurement uses a tonometer, which 
measures cornea deflection caused by an applied air-flow [4], providing the 
ophthalmologist an easy, relatively cheap way to estimate IOP.  However, tonometry 
lacks accuracy because of assumptions of a “normal” cornea stiffness, while cornea 
stiffness varies from patient to patient. Tonometry is not readily adaptable to real-time 
measurements, and is not ideal for capturing transient spikes in IOP [5]–[7].  Different 
approaches have been proposed and developed to acquire better accuracy in tonometry 




Contemporary implantable IOP sensors can be divided into two categories based on 
the sensing technique: electrical or mechanical.  With proper signal processing and 
antennas or other techniques, these devices can transmit IOP data into storage wirelessly 
and the ophthalmologist could potentially assess if the patient needs further treatment.  
As an example on the electrical side, a research group recently showed that a flexible, 
capacitive IOP sensor occupying the whole anterior chamber of a mouse cadaver eye can 
simultaneously record IOP and transmit it through a built-in antenna [25], [27], [47].  
Porcine eyes and soft human body model [26], [29] were also used to determine the 
performance of the device in what is proposed to be a better model of the human eye.  
Though the flexible structure of the IOP sensor minimized the likelihood of scratching 
tissues in the anterior chamber [25] and RF wireless charging minimized the size of the 
device by eliminating the battery [26], [27], this device was still too big to be implanted 
into the human eye without blocking the incoming light through the pupil when dilated.  
In addition, lack of a securing mechanism can be an issue when transferring these IOP 
sensors designed to fit in mouse eyes into human eyes since these IOP sensors may move 
around inside the anterior chamber and cause problems.  In another example,  a group 
proposed a capacitive IOP sensor with a solar battery and an antenna that could detect 
and record the IOP value every 15 minutes and store it in memory [22], [24], [99].  The 
data could be retrieved by the patient everyday through wireless communication to an 
external device.  Because this IOP sensor had a computing system and a power supply 
unit, it was claimed as the first “cubic-millimeter computer” in the world [24].  While the 
system is quite impressive, it is relatively complex and expensive.  A third group 




change and transmit signals through resonant circuitry [100].  Instead of capacitive IOP 
sensors using the capacitance change due to the deflection or displacement of two parallel 
plates under pressure, B. Ziaie et al. developed and tested piezoresistive IOP sensors that 
measured the pressure difference between the choroid and the sclera [32].  Testing was 
performed in three human cadaver eyes under 10 to 47mmHg.  However, these devices 
were too big to be fully implanted into the eye, and the fact that they needed physical 
connections to external equipment makes animal experiments difficult.   
In contrast, unpowered mechanical IOP sensors using parylene-C as Bourdon tubes 
to sense the pressure change have been demonstrated [36], [37], [39], [40], [101], [102].  
Pressure resolution with in vitro testing in water was 3.56mmHg, and the sensitivity for 
ex vivo testing in several enucleated porcine eyes was 8.72 μm/mmHg for a the dynamic 
range of 29 to 88mmHg [36].  Mounting techniques for the sensor on the iris were also 
discussed and found successful for a 1 month period on the iris of rabbit cadaver eyes 
[36], [37].   
Despite the fact that electrical IOP sensors can monitor and store IOP data on a 
constant basis, unpowered IOP sensors have shown advantages over other IOP sensors, 
since they need no energy source, minimize the cost for fabrication, and simplify the 
design.  Because Bourdon-tube IOP sensors have drawbacks such as requiring expensive 
cleanroom fabrication processes and a relatively large size that can block the optical path 
via the pupil at night, we propose an approach using a manometer-based microfluidic 
device designed for periodic monitoring of IOP in glaucoma patients.  The principle for 
our IOP sensor is similar to a manometer and involves a dye solution in a pressure-




the membrane that pushes the dye solution out of the sensing pad.  The movement of 
sensing dye corresponding to a change in pressure can be measured and calibrated to 
monitor IOP.  This sensor can be implanted either in the lens capsular bag (referred to as 
an intracapsular IOP sensor) or sandwiched between the conjunctiva and the sclera 
(referred as a subconjunctival IOP sensor).   
Materials and Methods 
Design of Intracapsular IOP Sensors 
The intracapsular IOP sensor was our initial IOP sensor design and was intended to 
be implanted in the lens capsular bag after cataract surgery.  For reference, basic eye 
anatomy is shown in Figure 1.  The intracapsular IOP sensor [103], is based on the design 
of a capsule drug ring, which is placed around an intraocular lens (IOL) and used  to 
deliver Avastin to the back of the eye for the treatment of age-related macular 
degeneration.  Our initial efforts focused on a semicircular IOP sensor that could be 
placed into the capsular bag in a manner similar to that of the capsule drug ring.  Figure 
2a shows the design of the intracapsular IOP sensor, in which dye located in the sensing 
pad is be squeezed into a channel at a rate dependent on the pressure in the eye.  Figure 
2b shows a fabricated intracapsular IOP sensor placed on top of a human cornea.   
The subconjunctival IOP sensor is designed to be placed between the conjunctiva 
and the sclera, and a basic design is shown in Figure 3.  A sensing pad filled with an IR 
sensitive fluorescent dye pushes the dye into the channel when pressure is applied on a 
sensing membrane on top of the sensing pad.  Depending on the length of the dye inside 
the channel as a function of applied pressure, a calibration curve can be generated and, 









Figure 2 Intracapsular IOP sensors (a) Illustration of an intracapsular IOP sensor; (b) an 




Figure 3 Illustration of a subconjunctival IOP sensor 





























length measurement.   
The subconjunctival IOP sensors are implanted between the conjunctiva and the 
sclera, where there is not only no risk of blocking the light coming through the pupil, but 
also the IOP value can be measure accurately. Ziaie et al. have shown that IOP sensors 
mounted between the conjunctiva and the sclera can accurately measure IOP between 10 
to 47mmHg [32].  In order to fit in the subconjunctival space, a 8x5x2 mm dimension 
limit has to be achieved so the patient will not feel discomfort.   
When a pressure is applied to the sensing pad, the dye begins to move into the 
sensing channel and to compress the air that is in the channel.  The pressure inside this 
channel will eventually build up and prevent further movement of the dye.  To allow the 
dye to travel more easily inside the channel, two relatively large triangle-shaped air 
reservoirs are placed at the end of the channel to store the trapped air from the sensing 
channel and reduce the pressure build-up in the channel and the two reservoirs 
themselves.  The reservoir dimensions are based on the volume of the channel and 
sensing pad and the maximum allowable pressure buildup in the channel as calculated 
using the ideal gas law and a square membrane deflection equation under constant, 
distributed loads.   
Materials 
The intracapsular IOP sensor consists of a base made of polymethylmethacrylate 
(PMMA) or polydimethylsiloxane (PDMS) and a silicone elastomer sensing membrane 
(HT6135 and HT6210, Bisco).  For the subconjunctival IOP sensor, PDMS was chosen 
as the structural material due to its biocompatibility [104], [105], the ability to form fine 




For the dye in either the intracapsular or the subconjunctival IOP sensors, either IC-
Green [106] (17478-701-02, Akorn) or AK-Fluor 10% (17478-243-10, Akorn) [107] 
diluted with PBS into 1% AK-Fluor was chosen to be the sensing dye in the sensing pad.  
Both dyes are known to be biocompatible in the eye and have been used for intraocular 
staining for decades.  An additional layer made of either a glass cover slip or PDMS was 
added on top of the PDMS membrane in the subconjunctival IOP sensor to prevent the 
channel and the air reservoirs from being under pressure when testing.   
Fabrication 
The intracapsular IOP sensor fabrication started by carving the PMMA base using a 
laser ablation machine (VLS 3.60, Universal Laser Systems) with a desired channel 
geometry, as shown in Figure 2a, A silane mixture to bond the PMMA base to the 
silicone elastomer was prepared by mixing aminopropyltriethoxysilane (APTES) and 
bistrimethoxysilylpropylamine (BTMSPA) in isopropanol at a 1:1:20 ratio and applied on 
top of the PMMA.  Before bonding, the PMMA base was typically roughened with sand 
paper to help the bonding mixture adhere to the PMMA.  The bonding surfaces were 
activated using a corona plasma treatment (LM4243-05, Enercon) on both the PMMA 
and the silicone elastomer for 15 minutes after applying the mixture onto the PMMA.  
Then, the silicone elastomer was placed on top of the PMMA, clamped, and incubated at 
65°C for at least 14 hours.  The IC-Green dye was then injected into the sensing pad, and 
this IOP sensor was ready to be tested.   
For the subconjunctival IOP sensors, the same silicone-to-PMMA bonding was first 
tried, but a poor outcome in the device integrity was quickly observed, and the material of 




The subconjunctival IOP sensors were made of PDMS using soft lithography techniques.  
The soft lithography mold was made from a layer of double-coated tape (9019, 3M) and 
two layers of removable film (InstaChange 15 SM4, Gerber Scientific) that were placed 
on a glass slide (8201, Premiere).  Laser ablation was used to carve the desired feature 
into the tape, and in this case, the double-coated tape, which was 28μm thick, contained 
the sensing channel and the combination of all three layers contained the sensing pad and 
air reservoirs, making them ~368μm thick.  Low-power laser cutting was used to cut the 
tape layer by layer, and each layer was peeled after each laser cutting pass.  After laser 
cutting, the glass slide with the tape mold was attached to a Petri dish (25384-302, VWR) 
by an adhesive (4011, Loctite) to serve as a container for the uncured PDMS.  The PDMS 
was prepared by mixing the PDMS liquid and the PDMS curing agent in a 10:1 ratio and 
then degassing.  The uncured PDMS then was poured into the mold and baked at 65°C in 
an oven.  A 20μm PDMS membrane was generated by pouring uncured PDMS on the top 
surface of a Petri dish cover and spinning at 3000rpm for 1 minute.  Since bonding an 
extremely thin PDMS membrane on a PDMS piece is difficult, partially cured PDMS was 
used [108], in which the PDMS base – as shown in Figure 3 – was baked for 55 to 65 
minutes, and the PDMS membrane was baked for 40 minutes.  Then, the PDMS base was 
carefully peeled from the mold and placed upside-down on the PDMS membrane, and 
baked for another 2 hours in the incubator at 65°C.   
Since only the sensing pad was designed to be exposed to the applied pressure, a 
protective layer made of a glass cover slip (48366-067, VWR) or a 500μm PDMS layer 
(10:2 liquid to curing agent ratio) was designed to be placed on top of the PDMS 




design with glass cover slip as the protective layer, a window is cut in the glass cover slip 
using the laser and a corona air plasma was applied on both the PDMS membrane 
(already bonded with a PDMS base using a partially-cured technique) and the glass cover 
slip for 5 minutes.  For the design with PDMS as the protective layer, the corona air 
plasma was used to bond the PDMS protective layer with the PDMS membrane.  For 
both protective layer manufacturing processes, a 1-hour 65°C postbake was performed 
with the sensor clamped.  
Pressure Testing Stations and Pressure Testing Settings 
In order to simulate the intraocular pressure change, which typically ranges from 0 
to 50mmHg, either compressed air or water was used to pressurize the IOP sensor.  For 
the compressed air pressure station, compressed air passes through a pressure regulator to 
reach a pressure of less than 100mmHg and then goes into both the pressure gauge and 
the base for holding an IOP sensor.  An IOP sensor was sandwiched in the base of the 
pressure testing station, and a hole for the outlet of the compressed air directly accessed 
the sensing pad  The pressure gauge read the current pressure, which was controlled by a 
pressure regulator, and an optical image of the sensing channel was recorded using a 
camera (MD900E, Amscope).  The images were stored on a connected computer for later 
data analysis.  The pressure gauge had a precision of 0.2mmHg pressure difference.  All 
the intracapsular sensors were tested with this compressed air pressure station.  The 
subconjunctival sensors used a different system since this pressure testing station was not 
particularly flexible and needed to be modified for every design, the pressure distribution 
was not well controlled, and the natural environment for these sensors is liquid, not gas.  




column and the IOP sensor was placed at the bottom of the column. The height of the 
water column was varied to simulate changes in the IOP.   
For the subconjunctival IOP sensors, optical coherence tomography (OCT) images 
were also collected of the fluorescent dyes to verify that these dyes could be used to 
measure the length of the pressure measurement column. Some of the subconjunctival 
IOP sensors were covered with a piece of swine conjunctiva in order to verify if the 
signal is readable through the conjunctiva to verify whether or not the OCT imaging 
could be used in a real eye to collect the pressure repeatedly and noninvasively.   
Results and Discussion 
Fabrication Results 
Several designs and fabrication processes were tried before finalizing the 
subconjunctival IOP sensor tested in the hydraulic pressure station.  Bonding issues were 
observed in the preliminary subconjunctival IOP sensors with silicone-to-PMMA 
bonding.  Later subconjunctival IOP sensor design using PDMS achieved a better signal 
consistency, and even sensors with air bubbles trapped in the sensing pad could produce a 
readable signal in the hydraulic pressure station.  Images of some of the fabricated 
devices are shown in Figure 4.   
Bonding Issues for Subconjunctival IOP Sensors 
In the beginning, two kinds of 254µm silicone elastomer sensing membranes 
(HT6135 and HT6210, Bisco) were chosen and bonded with the PDMS base.  The 
HT6135 silicone elastomer had a smoother surface, which would result in better bonding, 
since corona plasma bonding of PDMS to silicone requires a flat surface for contacts; its 




deform when pressure was applied.  Since the IOP sensor required a deformable and soft 
material to serve as its sensing membrane, Bisco HT6210 with 10 durometer was chosen 
for the device though its surface was rougher than HT6135’s.  The lower durometer gave 
a better deformation of the membrane under pressure and led to a greater sensitivity in 
theory.  Experiments showed that the IOP sensor with a HT6210 silicone elastomer could 
generate a representative dye length under applied pressure, but none of the HT6135 ones 
could.   
Nevertheless, surface roughness resulted in difficulty for bonding when using 
corona plasma so that bubbles developed between the silicone membrane and the PDMS 
base, leading to leaks and failure of the device.   
In order to get a better bond without losing the deformability of the sensing 
membrane, a thin PDMS membrane was introduced to take the place of the silicone 
elastomer.  Though its Young’s modulus was more than that for silicone elastomers, the 
thin PDMS membrane saw a reasonable deformation under applied pressure.  The air 
bubble issue was solved by using the partially cured PDMS method, and the repeatability 
was good, so about 80% of the samples could form a consistent structure, leading to more 
 





repeatable testing results.  Figure 4 shows PDMS-based subconjunctival IOP sensors 
filled with either IC-Green (left) or AK-Fluor (right).  The transparency of the PDMS 
sensing membrane results in a clearer image compared with the PMMA-based 
intracapsular IOP sensors because the measurement image can be taken from the thinner 
(membrane) side instead of the thicker (base) side of the sensors.   
Air Bubbles for One of the Particular Subconjunctival IOP Sensors 
Air bubbles occasionally formed in the sensing pads during loading of the sensing 
dye.  The bubbles were not always problematic.  For the subconjunctival IOP sensors, 
one of the samples that experienced an air bubble in the sensing pad while testing under 
hydraulic pressure, showed that it could still obtain the same sensitivity when measuring 
pressure, but it had a larger offset than the others.  The bubbles appeared to form when 
the dye was injected into the acrylic square tube of the hydraulic system and went into the 
sensing pad through the injection hole for filling the dye into the sensor.  This situation 
could be minimized since there was no air inside the eye and therefore no air bubble 
would be generated outside of the IOP sensor.  Even if this situation happened, the 
ophthalmologist could still get a pressure readout according to the dye length 
measurement by just applying the offset value.   
Intracapsular IOP Sensor Testing 
The corresponding dye length inside the channel based on different applied 
pressure was recorded in order to compare the different response in intracapsular sensors.  
Three of the intracapsular IOP sensors achieved a sensitivity of 0.038, 0.044, and 
0.085mm/mmHg, respectively.  A graph of the dye length in the intracapsular IOP sensor 




recorded, as shown in Figure 5.   
Subconjunctival IOP Sensor Pressure Reading Result 
After acquiring images of the IOP sensor under different applied pressures, Image J 
(public resource, NIH) was used to calculate the dye length.  AutoCAD was also used to 
help calculate the effective dye length around the corners in the channel.  Images of 
subconjunctival IOP sensors under hydraulic pressure were recorded by either the 
Amscope or the OCT.  The former was performed for most of the samples, and the length 
of the dye (IC-Green or AK-Fluor) was recorded for data analysis.   
Figure 6 shows the average dye length under increasing and decreasing pressure 
with error bars based on the results of three different devices measured using the 
Amscope and measurements for an OCT trial (using AK-Fluor).  Error bars for individual  
 



























Figure 6 Graph for dye length versus pressure for subconjunctival IOP sensors 
devices were much smaller.  Except for the OCT sample’s 50mmHg reading, most of the 
OCT’s readings fell in the margin of error region for the IC-Green sample 
measurement,suggesting that the methods are comparable and compatible.  For an 
increasing pressure, the sensitivity of average IC-Green dye length in the normal IOP 
region was 0.099mm/mmHg and in the glaucoma IOP region the sensitivity increased to 
0.34 mm/mmHg.  The reason for the difference in sensitivity appears to that the sensing 
pad is not fully filled, so a pressure must build up and the dye must fill potentially empty 
space before moving into the sensing channel.  Once these initial effects are overcome, 
the dye can move through the channel readily, providing the higher sensitivity in the 
pressure range of interest – the one between 22 to 35mmHg.  The high sensitivity of the 
IOP sensor in this pressure region is advantageous for an ophthalmologist to discriminate 






































range are relatively less important, the range of high sensitivity can likely be expanded by 
improved dye loading methods. 
Figure 7 shows the Amscope image of a subconjunctival IOP sensor under 
hydraulic pressures of 0 to 45mmHg.  The contrast of the dye using the IC-Green and the 
Amscope was limited, making dye length measurements more difficult.  In contrast, the 
OCT image with AK Fluor-dye, shown in Figure 8, gives a clear dye signal compared to 
the Amscope one.  In the infrared and spectrum mode of the OCT, the 1% AK-Fluor dye 
was bright and easy to observe.  This sensor, shown in Figure 6, had a sensitivity of 
0.065mm/mmHg in the normal intraocular pressure region, and a 0.481mm/mmHg 
sensitivity in the glaucoma intraocular pressure region.  The results suggest that either 
AK-Fluor or IC-Green could serve as the dye for the IOP sensor, but that use of OCT 
with an IR fluorescent dye might be preferred.   
To test the ability to read the sensor through the outer eye tissues, several swine 
conjunctivas were harvested and placed over these sensors to see if the OCT could image 
the dye through a typical eye tissue, and it was shown that in fluorescence mode, the 
OCT could distinguish the dye from the background.  Since swine conjunctiva is thicker 
than human conjunctiva, it is highly likely that the dye could be sensed when implanted 
in a human eye and observed through the human conjunctiva.   
Hysteresis of the Sensors 
Both intracapsular and subconjunctival IOP sensors were tested with increasing 
pressure, but only the subconjunctival IOP sensors were tested with decreasing pressure.  
Hysteresis in the measured signals, or a difference between the increasing and decreasing 





Figure 7 Amscope image of the subconjunctival IOP sensor with IC-Green dye under 0 to 





Figure 8 OCT image of the subconjunctival IOP sensor with 1% AK-Fluor dye under 0 to 






the dye length for a particular pressure was different when the pressure was dropping 
instead of climbing to a particular value.  Hysteresis happened for all the subconjunctival 
IOP as shown in the difference between two average lines in Figure 6.  This hysteresis 
appears to be mostly associated with bubbles in the sensing chamber, which seem to be 
due both to the loading of the dye and the gas permeability of PDMS sensing membrane.  
Some of the bubbles occur when the air originally in the channel and the sensing pad is 
compressed when filling the sensing pad with the dye, and the air get further compressed 
when the hydraulic pressure is applied.  Some of the compressed gas may be pushed out 
through the PDMS and so a vacuum does not form when the pressure on the sensing pad 
is released, so the dye column is not pulled back into the sensing chamber as readily.  
Overall, for both the increasing and decreasing paths, there seems to be an “inertia” effect, 
in that once the dye begins to move, it moves more easily.  The hysteresis is also not 
consistent in that some devices possess a lower hysteresis and the dye would go all the 
way back into the sensing pad at 0mmHg; while in other cases, the dye would leave a 
1.5mm length in the channel at 0mmHg, even though all the experiments started from 
0mm of dye in the channel.  For comparison, hysteresis was not discussed at all in other 
IOP sensor publications [12]–[14], [23]–[27], [29], [32], [36]–[40], [47] and was only 
mentioned briefly in the work of Wise et al. [22].  Based on the likely causes of the 
hysteresis, the best solutions to reduce the hysteresis would likely be a channel coating to 
reduce capillary forces, elimination of dead volumes or trapped bubbles by better dye 






Two types of IOP sensors have been designed, fabricated and tested.  The 
subconjunctival IOP sensors possess a more broad application compared to the 
intracapsular IOP sensors because they can be used with any patient and they are easier to 
to both implant and observe.   
Conclusion for Intracapsular IOP Sensors 
Over 50 intracapsular IOP sensors were fabricated and tested; three final devices 
using the design reported in this paper were shown to show repeatable and sensitive 
results for pressure measurement in the range of pressures relevant to glaucoma patients.  
The PMMA base itself had some drawbacks, including that the dye would tend to stick 
on the wall of the channel, resulting in poor sensitivity of the sensor.  In addition, the 
silicone to PMMA bonding challenges led to inconsistent sensor dimensions leading to 
inconsistent measurement results between sensors.  Moreover, the amount of dye filling 
the sensing pad was difficult to control, which also affected the uniformity of results from 
sensor to sensor.  In addition, the signal can only be observed through the thicker (base) 
side of the sensor because of the non-transparent sensing membrane, leading to a 
relatively blurry image.   
Conclusions for Subconjunctival IOP Sensors 
Nearly 70 subconjunctival IOP sensors were fabricated and tested before a final 
design was developed using the partially cured PDMS technique to bond two PDMS 
components together, and seven devices based on the final design worked such that the 
dye could move forward and/or backward based on the applied pressure.  These devices 




intraocular pressure region (below 22mmHg) and a much higher one in the glaucoma 
intraocular pressure region (22-35mmHg), which is of particular interest in this work.  
The devices were shown to work with IC-Green and AK-Fluor dyes.  In addition, the 
AK-Fluor signal was readable when covering the subconjunctival IOP sensor with a piece 
of swine conjunctiva.  Moreover, though hysteresis did happen, another calibration curve 
for decreasing pressure can be generated with an offset from the calibration curve under 
increasing pressure.  Since these sensors were tested in a water-based hydraulic system, 
these sensors were shown to be waterproof and could function inside the eye.  In order to 
achieve better signal consistency, additional tests with identical devices should be 
performed to acquire more data for the average dye length calibration curves in order to 
get a more precise prediction of intraocular pressure based on the dye length 
measurement.   
 CHAPTER 3 
PDMS DRUG DELIVERY DEVICES: POTENTIAL APPLICATION IN  
NERVE REGENERATION 
Introduction 
Peripheral nerve injuries affect 2.8% of trauma patients [49], significantly reducing 
their quality of life due to the loss of function and sensory for extremities..  Most nerve 
repair surgeries have poor outcomes with contemporary treatments [45], spurring 
research into alternative methods to address this clinical need.   
Currently, end-to-end tension-free nerve re-approximation is performed for 
peripheral nerve gaps less than 1cm, while special bridging techniques are required for 
gaps larger than 1-2cm [52].  The preferred clinical bridging technique uses autologous 
nerve grafts (autografts), which not only require additional surgery, but also lead to donor 
site deficits in function or sensation [55].  Thus, there is significant need for methods of 
nerve repair that avoid these concerns. 
Following a peripheral nerve injury, axons will tend to regrow or regenerate and 
cross short gaps, though they need guidance in order to find their target [109].  Both 
natural and synthetic materials have been used to repair nerve gaps ranging from 5 to 
80mm [59], including nerve grafts and artificial tubes made from collagen, PLGA, 
silicone or polyurethane [52], [110].  Additionally, several drugs have been shown to be 
effective in promoting axonal outgrowth across the nerve gap [56].  A 3-month study of 




in repairing peripheral nerve gaps [78].  Collagen tubes loaded with NGF alone, or in 
combination with glial cell line-driven neurotrophic factor (GDNF), have been shown to 
enhance axon growth [111], [112].  In cell culture studies, NGF or GDNF with a 
concentration of 0.01 to 100ng/mL have resulted in significant axon growth in chick 
dorsal root ganglion cells.  Several review papers suggest that better peripheral nerve 
regeneration can be expected by either the presence of physical bridge or the supply of 
neurotrophins or growth factors [52], [56], [57], [59], [93], [109], [110], [113]–[115].  
Though some tissue-engineered conduits provide results comparable with autologous 
grafts [91], it is difficult to change either the growth factor or the dimension of the device 
based on different target nerve gaps.  Thus, a device that is easily customizable in both 
dimension and drugs (growth factors) of interest is proposed in this paper.   
The work included in this paper proposes a new, easily tailored approach to 
delivering drugs to treat peripheral nerve gaps.  The general concept is to create a nerve 
guidance conduit surrounded by a drug reservoir that delivers drug into the lumen of the 
conduit, thereby encouraging rapid, directed nerve growth.  Switching drugs should be 
straightforward as the kinetics of release can readily be modeled and calculated, in 
comparison to techniques that require material degradation.  The general concept for the 
device is shown in Figure 9.  This work focuses on a polydimethylsiloxane (PDMS) 
device with the comparison between using either filter membranes or diffusion holes as 
diffusion windows, with several different sets of nerve conduits (devices) used to 
demonstrate different molecule release from drug reservoirs into the environment (a 
receiver chamber).  Prior to this work, a PDMS device without a nerve conduit was first 





Figure 9 The schematic diagram of the device showing membrane placement and the 
assembly of the device on the nerve. Purple arrow indicates the release route of the drug 
 
suggesting that the concept of drug release through a membrane on a nerve conduit could 
work (data unpublished).  Then, a PDMS device with a nerve conduit, schematically 
shown in Figure 9, was developed and showed the ability to deliver bovine serum 
albumin (BSA) for 6 days.  In this 6-day study, 100mg/mL BSA solution was filled into 
PDMS devices (n=3) with a PES filter membrane as the diffusion window.  All three 
fabricated devices released the drug, and two out of three PDMS devices released BSA at 
a rate that would be of interest for drug delivery and with reasonable release kinetics over 
the 6-day period.  The best devices had a higher release rate in the first 61 hours and a 
slower one for the remaining period.  The low release device likely had a blockage 
caused by either an air bubble or adhesive on the membrane [55].  This paper expands on 
this preliminary work by first studying the same PDMS device design when delivering 
NGF and then explores a potentially improved design of the PDMS device using 
diffusion holes to replace the filter membrane as the diffusion window.  This second 
device will be used to deliver Dextran as a drug stimulant for 31 days.  The Dextran 
PCU inner conduit 
Nerve Drug (in the drug reservoir) 
PDMS outer 
conduit  
Diffusion window: filter 
membrane / diffusion 
hole 
Nerve axons 





model was chosen for its low cost, ease of use, stability, and similar size to the drugs of 
interest.   
Materials and Methods 
In this work, a 21-day NGF diffusion study was first conducted using PDMS 
devices with a PES filter membrane as the diffusion window.  The results of the initial 
NGF study suggested some changes should be made, so modified PDMS devices using 
diffusion through holes as the diffusion windows were tested with Dextran and compared 
to the release kinetics of PDMS devices using PES filter membranes in a 10-day study.   
A 21-day NGF Diffusion Release Study 
Devices made of PDMS with a membrane for release were designed, manufactured, 
and tested using NGF in a 21 day experiment.  The amount of NGF released was 
measured and used to improve the design and construction of the device. 
Design 
The concept behind this work is that bridging nerve gaps requires a physical 
structure to guide axon growth in addition to drug release to encourage rapid growth.  
Therefore, we designed a modified PDMS device capable of delivering a drug into the 
lumen of a nerve conduit that was designed to bridge a nerve gap [55].  The space 
between two concentric tubes served as a reservoir for storing the desired drug.  When 
released, the drug will diffuse through a filter membrane and a window to enter the nerve 
conduit (inner tube), and contact the proximal nerve stump to promote axon growth.  
Figure 10 shows the designed storage reservoir of the drug, and the release route to the 




device.   
To form the nerve regeneration device, two tubes with different dimensions were 
aligned to form a set of concentric tubes, with the lumen between the inner tube (nerve 
conduit) and the outer tube serving as the drug reservoir, as shown in Figure 9.  A 
polycarbonate-urethane (PCU) [103] tube was chosen to serve as the inner tube.  The 
encircling drug reservoir made of PDMS was formed by the space between the inner 
conduit and the PDMS outer conduit.  The PDMS outer conduits were cut into 8.6mm 
outer diameter and 5mm inner diameter tubes.  A 12-mm-long PDMS outer conduit and a 
15-mm-long PCU inner conduit were assembled together with two ring-shaped PDMS 
plugs at each end of the drug chamber, which resulted in a drug reservoir volume ranging 
from 50 to 100µL, depending on the sealing ring location.   
Fabrication 
The fabrication process of these PDMS devices for NGF delivery can be divided 
into the manufacturing of each part, assembly of the device, and drug filling.  Before 
 
Figure 10 Photograph of the PDMS device for NGF release test  
PCU inner 







assembly of the device, the PDMS outer conduit and plugs, the filter membrane and PCU 
inner conduit were prepared. 
For making the parts, The PDMS components were made by pouring 10:1 ratio 
PDMS solution into 1.5mL Eppendorf vials and polystyrene Petri dishes and then baking 
them for 2 hours in a 65ºC incubator.  PDMS outer conduits were obtained by carefully 
peeling the rigid PDMS column from the Eppendorf vial and punching a hole through the 
cylinder with a 5mm biopunch.  PDMS plugs were formed by punching concentric circles 
on the PDMS slab in the Petri dish mold with 5mm and 1.5mm biopunches.   
For the PCU inner conduit, pellets of thermoplastic PCU (BioNate II, DSM 
Biomedical, Berkeley, CA) were heat extruded into tubes with a 1.5mm outer diameter 
and a 1.3mm inner diameter.  It was further cut into 15mm long pieces, with an 
approximately 1mm x 2.5mm window drilled by a Dremel tool.  A piece of PES filter 
membrane was cut into a rectangular shape to cover the window.  Loctite 4011 adhesive 
(18680, Loctite, Westlake, OH) was applied along the edge of the window to attach the 
filter membrane without blocking the pores on the membrane [55].   
Figure 10 shows the device before assembly.  When assembling, one side of the 
PDMS plug was squeezed into the PDMS outer conduit followed by the application of 
uncured PDMS and RTV silicone sealant (RTV 734, 2307774-1008, Dow Corning, 
Midland, MI) to seal the end.  The device was then baked for 1 hour at 65ºC to ensure 
proper sealing of the device.  The other end of the PDMS outer conduit remained open 
until NGF was injected into the drug reservoir.   
When filling the reservoir with NGF, the maximum amount of NGF solution was 




diffusion into the nerve conduit.  Therefore, around 50 to 100µL of the desired drug was 
injected into the drug reservoir.  After filling, the uncapped end of the PDMS outer 
conduit was sealed with a PDMS plug and RTV silicone sealant, followed by curing at 
room temperature for 15 minutes.  Unlike uncured PDMS, RTV silicone sealant requires 
no elevated temperature to cure and will preserve the bioactivity of the desired drug.   
Test setup for NGF Diffusion Experiments 
The NGF release experiments were similar to the BSA diffusion experiments 
performed using a related device [116]; instruments, controls, and sampling occurred in a 
similar manner. The differences will be highlighted.   
The 21-day NGF diffusion study started with the preparation of the base NGF 
solution.  Because previous studies had shown that the combination of a PES filter 
membrane and polyvinyl alcohol (PVA) with a 50mg/mL concentration can help generate 
a controlled release rate [41], PVA was mixed with NGF.  The NGF solution was 
prepared by dissolving 0.1mg of NGF powder (N2513, Sigma-Aldrich, St. Louis, MO) in 
1mL of PBS solution containing 0.1% BSA.  The NGF solution was diluted with 
50mg/mL PVA to either 0.7µg/mL or 1.4ng/mL NGF final concentrations for devices or 
a reference sample, respectively, as shown in Table 4.  NGF solution was filled into the 
drug reservoir in such a way as to minimize the volume of air in the drug reservoir, which 
would potentially block the release across the filter membrane.   
The NGF solution was loaded into devices according to the dosage shown in Table 
4.  The positive NGF control without any drug delivery device was designed so that a 
maximum concentration of NGF could be established and measured in the ELISA assay 




Table 4 List of samples corresponding to drug and receiver chamber for NGF diffusion 
experiments 







Positive control  105µL 
0.7µg/mL NGF 
9800pg/mL 
Reference sample 105µL 
1.4ng/mL NGF 
19.6pg/mL 
Negative control 70µL 1x PBS 
with 0.1% BSA 
0 
Device A 82µL 0.7µg/mL 
NGF 
7653.3pg/mL 
Device B 105µL 
0.7µg/mL NGF 
9800pg/mL 
Device C 80µL 0.7µg/mL 
NGF 
7466.7pg/mL 
NGF signal in ELISA when only a small concentration of NGF is present.  The 
concentration was chose to be the same as if 1/500 of the NGF is released from the drug 
reservoir into the receiver chamber.  A negative control consisting of a PBS filled device 
was prepared in order to identify the noise.  Glass amber vials (27002-U, Sigma-Aldrich, 
St. Louis, MO) filled with 7.5mL PBS solution were used as receiver chambers for all the 
groups.   
The experiment was performed at room temperature and set on an rotary shaker for 
3 weeks while samples were taken after 1, 37, 161, 335 and 504 hours from setup. 
Samples of 500µL were taken from each vial at each time period and stored at -20°C, 
while 500µL PBS solution with 0.1% BSA were refilled into each vial in order to 




transferred onto a 96-welled plate for ELISA (ab100757, Abcam, Cambridge, MA) at the 
same time after the last set of samples was collected.  For the ELISA plate, standards 
were prepared at 20.58, 61.73, 185.2, 555.6, 1666, 5000 and 15000 pg/mL in order to 
cover both extremely low release (e.g., 19.6pg/mL) and extremely high release (e.g., 
9800pg/mL) scenarios.  The instructions with the ELISA kit were followed and the 
results were read at 450nm with the plate reader.    
A 31-day Dextran Diffusion Study 
As a possible improvement for the PDMS devices with PES filter membranes, 
PDMS devices using through holes (diffusion holes) were proposed in order to possibly 
achieve more consistent release kinetics and also allow for lower release rates.  The 
design of these PDMS devices with diffusion holes is introduced, followed by the 
fabrication process of these PDMS devices with either PES filter membrane or diffusion 
holes.  A 31-day release study was conducted to verify and compare the release kinetics 
of PDMS devices with diffusion holes and PDMS devices with PES filter membranes for 
delivering Dextran.   
Design and Modeling 
Because the adhesive applied on the PES filter membrane can block the filter 
window and reduce its release capabilities, while also making the release inconsistent 
from device to device [55], [117], as was found in some of the devices releasing both 
BSA previously and NGF in this work, an alternative design using through holes 
(diffusion holes) on the inner conduit (PCU conduit) was proposed to replace the filter 




controlled, consistent release rate.  Thus, an experiment to compare the usefulness of 
diffusion holes rather than a membrane was developed. 
As the stability of the NGF had also come into question in some of the experiments, 
labeled 10kDa Dextran was used to simulate the NGF release in the tests of this device.  
In addition to being stable over the length of these experiments, Dextran is also much 
lower in cost, which made it a good candidate for these early device tests. 
To determine the appropriate size of the release holes and the optimal 
concentrations of drug in the release reservoir, a model based on Fick’s First Law of 
Diffusion was developed.  Fick’s First Law of Diffusion is given by 
    
     
  
, Equation 1 
where J is the diffusion flux (
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 ; and Δx is the distance between two stages.  Using Equation 1, a 
model was built to predict the final drug or polysaccharide concentration in the receiver 
chamber.  The model was used to optimize hole sizes and drug concentrations to ensure 
the concentrations of drug released were both within the detectable range of the 
measurement methods (between 30ng/mL to 250µg/mL) and consistent with dosage 
levels likely to increase growth of nerve tissues.   
The model was designed to represent the physical processes and geometry through 
which drug will leave the drug reservoir and reach either the nerve stump or the end of 
the drug delivery conduit.  The model can then be used to predict the Dextran 
concentration in the receiver chamber when the sink method is used.  The sink method is 




amount of fresh media each time a sample is collected [61], [71], [118], [119].  If the 
model is applied correctly, a proper starting donor chamber Dextran concentration and a 
diffusion hole dimension can be calculated to produce a detectable Dextran concentration 
in the receiver chamber.  Preliminary work showed that a Dextran concentration between 
30ng/mL and 250µg/mL is detectable in the plate reader.  Figure 11 shows the concept of 
this model, in which a drug reservoir (stage 0) filled with the desired drug releases the 
drug through diffusion holes into the inner conduit (stage 1).  The drug then diffuses from 
the inner conduit to the receiver chamber (stage 2).   
Two equations specific to this model and based on Equation 1 are:  
       
     
     
 Equation 2 
       
     
     
 Equation 3 
in which the diffusion flux between stages 0-1 and 1-2 are J0-1 and J1-2, respectively; the 
area for the diffusion filter or holes and inner conduit transverse cross-sectional area are 
A0-1 and A1-2, respectively; the concentration at stages 0, 1 and 2 are C0, C1 and C2,  
 
 












respectively; and the distance between stages 0-1 and 1-2 are Δx0-1 and Δx1-2, respectively.   
Because the diffusion in the inner conduit to the receiver chamber can go in two 
directions, the diffusion mass flow at steady-state is:  
                     Equation 4 
Also, the net drug increase (in mass) in the receiver chamber equals the net mass 
flux across the inner conduit in a given time; thus,  
    
              
 
 Equation 5 
where t is the time (s) allowed for diffusion, and V is the volume (m
3
) in the receiver 
chamber.  
From these equations, we can derive the concentration of the inner conduit just 
outside of the release holes (C1) as: 
   
                                     
                                               
 Equation 6 
Then, the concentration in the receiver chamber (C2) is:  
      
          
 
 Equation 7 
In this model, the diffusion coefficient for the 10kDa Dextran (0.00000130 cm
2
/s) 
is considered to be similar to the 0.00000126cm
2
/s diffusion coefficient for NGF [120].   
All calculations were conducted in Microsoft Excel, and after entering the 
parameters shown in Table 5, the concentrations in the receiver chamber after day 1, 5, 




Table 5 Fixed parameters for the model 
Description Notation Value  Unit 
Cross-sectional area in the inner 
conduit 
A1-2           m
2
 
Wall thickness of the inner 
conduit 
Δx0-1 100 µm 
Distance between the diffusion 
hole to the receiver chamber 
Δx1-2 10 mm 
Diffusion coefficient D 0.00000126    
 
 
Receiver chamber volume V 14 mL 






































Two sets (n=4) of PDMS devices, one with holes and one with membranes, and 
three sets of controls (n=4) were used in order to verify both the integrity of the device 
and the consistent release in the same design.  Table 6 shows the modeling results for the 
Dextran concentration in the receiver chamber at different time points using the sink 
method for all three sets of the PDMS devices.  
PDMS devices using either the filter or diffusion holes as the diffusion window 
were proposed, with the latter expected to achieve a more consistent result in biomolecule 
release over a 31-day period, because they reduce the manufacturing defects associated 
with adhesive that can completely or partially block the diffusion window, making the 
release inconsistent across devices.  The primary control consisted of the PDMS device 
with neither the filter membrane nor the diffusion hole to verify the sealing of the device 
and detect any Dextran release through any other mechanisms.  The other controls 
consisted of reference samples with either high or low concentrations of Dextran.  These 
reference samples enabled both calibration and comparison of Dextran stability.  Because 












 day, these two sets of 
reference samples (n=4) were able to identify the Dextran signal fluctuation for a similar 
concentration of a net 5-day Dextran release in the 31-day period.  In these reference 
samples, the receiver chambers were filled with a Dextran concentration of either 6400 or 
32800ng/mL in 14mL PBS to simulate the Dextran signal of the 10
th
 day collection from 
the PDMS devices with either the diffusion holes or PES filter membranes, respectively.  
Table 7 shows the volume and design for each device and control used in this 31-day 
Dextran release study.  Reference samples M, N, O, P were prepared at a Dextran 




Table 7 PDMS devices and reference samples used in the 31-day Dextran release study 
Device number Design of the 
PDMS device 
Volume of 
Dextran (µL)  
Device A 
Four 40µm diffusion 
holes 
125 
Device B 140 
Device C 125 




Device F 125 
Device G 100 
Device H 125 
Device I 
Without filters or 
holes 
100 
Device J 125 
Device K 125 
Device L 125 
Dextran concentration of 32800ng/mL.  In addition to these reference samples, 14mLPBS 
was filled into 15mL centrifuge vials and served as the medium of the receiver chamber.   
Fabrication 
A fabrication process similar to the NGF devices was used to fabricate the PDMS 
devices used in the Dextran release study.  One change in this study is that the length of 
the PCU conduit increased from 15mm to 20mm so that better sealing at the ends could 
be achieved.  In addition, a 6mm biopunch instead of a 5mm biopunch was used so that a 
greater volume of the drug reservoir could be accessed.   
For the PDMS device with four 40µm holes, laser machining was used to create the 




Test setup for Dextran Diffusion Experiments 
Table 6 shows the design and expected Dextran concentration in the receiver 
chamber in a 31-day period, and Table 7 shows the approximate volume of Dextran 
loaded into each device.  Forty mg/mL Dextran was prepared by dissolving 25mg 
Dextran with PBS.  Undissolved Dextran was removed by centrifuge at 5000rpm for 5 
minutes, as suggested by the receiver chambers, with the lid sealed by parafilm.  The vial 
was wrapped in aluminum the manufacturer.  To lower both the adhesion on the glass 
walls and any evaporation through the lids, sterilized 15mL centrifuge vials were used as 
foil in order to both reduce evaporation and reduce signal degradation due to light 
exposure.  The vials (receiver chamber) were then placed on a rack and stored in a drawer 
without shaking to minimize the possibility of introducing air bubbles into the inner 
conduit, which will partially stop or lower the diffusion.  In addition, the sink method was 
 
Figure 12 Four 40µm hole drilled by laser on the PCU inner conduit of the PDMS device 




used in which the entire receiver chamber media was replaced with a fresh 14mL PBS 
every time after collection.  Each inner conduit was flushed 20 times with 400µL of the 
media in the receiver chamber to remove any trapped air bubbles. Reference samples M-
T did not contain any PDMS devices, but rather were filled with known concentrations of 
Dextran.  Unlike the device groups where the entire volume of receiver chamber fluid 
was removed, only three aliquots of 400µL samples were collected from the reference 
samples each time, with no fresh PBS placed into the receiver chambers.  Samples 
collected from both the devices and reference samples were stored at -20ºC and analyzed 
at the same time.  The plate reader was used with an excitation wavelength of 494nm and 
an emission wavelength of 521nm as appropriate for the Fluorescein dye on the Dextran.   
Results and Discussion 
Initial fabrication results suggested that the devices would be ready and able to 
release drugs as designed, which led to the 21-day NGF diffusion study where the results 
were comprised of the NGF release amount (in ng).  The results of the NGF study led us 
to complete the 31-day Dextran diffusion study.  The release data for both NGF and 
Dextran diffusion studies provided some interesting results which will be discussed. As 
noted, some of the results led to suggestions for a possible improvement of the design and 
fabrication process, and the results of these changes are addressed.   
A 21-day NGF Diffusion Study 
The scope of this 21-day NGF diffusion study was to reveal the diffusion kinetics 
of NGF in terms of NGF amount delivered in the given period.  Discussions for the 




and setting of both the device and the experiment.   
The fluid in the receiver chambers were collected over a period of 21 days as noted 
in the Methods section.  The NGF concentration in each sample was calculated from the 
enzyme-linked immunosorbent assay (ELISA) plate reading values according to an NGF 
calibration curve prepared with each measurement and consisting of NGF concentrations 
from 20 to 5000pg/mL.  After acquiring the NGF concentration in each sample, the 
concentration was converted into the NGF mass (in ng), and the data were summed to 
show the cumulative NGF release amount in the 21-day period, as shown in Figure 13.   
Because the NGF concentration of the high reference sample or positive control 
was 9800pg/mL, which exceeded the detectable range of the NGF calibration curve, it 
could not be plotted in Figure 13.   The negative control shown in Figure 13 set the noise 
level for the reading, and it showed that there was no statistical difference between the 
negative control, the low reference sample, and device A.  NGF release kinetics 
simulated by the proposed model showed that 30.8ng NGF was expected to be delivered 
into the receiver chamber at the end of 21 days, with a steadily decreasing delivery rate 
from day 1 to day 21.   
In Figure 13, the cumulative NGF amount released from device A stayed near zero, 
indicating that the PES filter in this device was likely blocked.  For device B, the large 
NGF release between the 1st hour and the 37th hour (1.5 days) suggested that this device 
was not sealed completely.  Twenty-three ng of NGF in device B was released during this 
period.  The decrease of the cumulative NGF amount after 37 hours (1.5 days) was likely 
due to either the degradation of the NGF over time, reducing its signal in the ELISA, or 




Device B also showed a lower cumulative NGF release in the 21-day period, though 
possessed a higher release at the 37
th
 hour (1.5day).  Because only 0.5mL out of 7.5mL of 
the receiver chamber media was collected, and no mixing was performed before 
collecting the sample, the NGF that was released early in the study remained in the 
receiver chamber for a long period of time, likely degrading and possibly swamping out 
any later release of NGF from the device.  For device C, the increase of the cumulative 
NGF amount from 211 to 561.4pg in the 21-day period indicated that the diffusion rate of 
NGF was greater than the degradation rate of NGF or the protein adhesion rate of NGF to 
the glass wall.   
Overall, this study suggested that some modifications to the experiments needed to 
be made.  First, the NGF “loss” over time could not be explained well and certainly a 
reduction in cumulative release over time is impossible, so the sinking method was 
developed to measure only any new drug release and avoid issues with degradation of 
 
Figure 13 Cumulative NGF amount released into the receiver chamber in a 21-day 
period.  Though device B showed a higher release compared with devices A and C, it still 






















molecules resident in the receiver chamber for a long period of time.  Second, it was not 
clear if the NGF was stable, so Dextran was chosen due to its improved stability.  Use of 
Dextran also allowed us to use a plate reader rather than an ELISA, which should reduce 
noise at these lower concentrations.  Third, the devices fabricated were quite inconsistent 
in their release, suggesting that modifications would need to be made to the 
manufacturing process. The prime culprit in the inconsistency seemed to be the 
membrane and possibly the adhesive that was used to attach the membrane.  Thus, 
devices using holes were developed to release the drug rather than an adhered membrane.  
The cause of the high release was not clear, and could be associated with either leakage 
or possibly drug on the outside of the device walls.  In either case, improved 
manufacturing methods were needed.  The results did suggest that there was potential for 
the devices to work, but an improved design was needed, leading to the 31-day Dextran 
study.   
A 31-day Dextran Diffusion Study 
As it was possible from our work with NGF that the NGF was degrading, we chose 
to use Dextran with an attached fluorophore to model NGF release and hopefully avoid 
this problem.  To assure that the Dextran and fluorophore were stable, during the 31-day 
experiment, a separate sample of Dextran at different concentrations was kept in the same 
environment to serve as a reference sample. The plate reader measurements from the low 
reference samples M-P and the high reference samples Q-T are shown in Figure 14.  Note 
that the M-P reference sample is expected to be in the range of the release from the 
devices with holes and the Q-T samples are expected to be closer to the release from 





Figure 14 Dextran concentration of reference samples M-P and Q-T in a 31-day period.  
The former represents the Dextran signal in net 5-day release from PDMS devices with 
filter membrane; the latter represents the one from PDMS devices with four 40µm holes 
a 7% standard deviation over the 31 days for  the Dextran concentration of 32800ng/mL, 
and a 3% standard deviation for the Dextran concentration of 6400ng/mL.  Both controls 
indicated that the Dextran signal was consistent in the 31-day period with reasonable 
signal fluctuation.   
The sealed devices (I-L) served as negative controls to both verify the sealing of the 
devices and provide a background signal for the devices designed to release drug.  One 
device showed a slow release reaching 0.2% of the total Dextran loaded on the device.  
The other three devices showed no release, indicating that the sealing for all four devices 
was reasonable and that the devices could be expected to perform without major leakage 
issues. Therefore, it is reasonable to assume all the Dextran detected in the receiver 
chamber for the device experiments is released from either the filter or the diffusion holes, 


























Devices A-D with four 40µm holes demonstrated a cumulative 3.8-9.0% Dextran 
release in the 31-day period, compared to modeling results showing a 10.2% Dextran 
release, as shown in Figure 15.  The coefficient of variation for the four devices was 0.41 
at day 31, suggesting there is still some manufacturing variability or possibly random 
interference from air bubbles.  Nevertheless, continuous release was observed for all 
devices with holes (A-D) in the 31-day period.   
The release profile shows a bit of a burst effect, meaning the delivery was relatively 
high the first day, followed by a fairly steady, nearly zero order, release over the last 4 
weeks.  Much of the variation associated with device C can be entirely attributed to the be 
related to small amounts of Dextran being absorbed to the outside of the devices during 
filling, as in many cases the Dextran leaks out of the device when being filled.  The 
outside of the devices are washed thoroughly, but there may still be some material on the 
surface.  Another possibility is the drug is essentially released somewhat in advance into 
 





















the inner lumen through the drug delivery holes, as the devices are loaded and then stored 
briefly.  Some drug may be pushed through the drug delivery holes or membranes during 
loading, or variation in burst release the first day.  The cause of the burst release is not 
clear, but it may allowed to release through the holes or membranes during storage, and 
then released quickly once placed in the receiver chambers.  In any case, a small burst 
effect is not necessarily a problem and can be advantageous in helping to rapidly start the 
growth of axons in the conduit.   
Some of the variation in the release may be associated with the laser drilling 
process, as the laser drilling process is somewhat challenging to control for these small, 
rounded devices.  A 5µm measurement error was expected and images of the holes 
indicates that they have some taper as they cross the wall of the inner conduit, leading to 
some reduction in diffusion area.  Removal of undissolved Dextran might also contribute 
to the relatively low release profile, when compared to the model predictions, so that less 
Dextran was filled in the device than designed.    
Devices E-F with PES filter membrane showed a wide variety of release rates, just 
as found for earlier work with NGF, as shown in Figure 16.  Device E showed no release 
in the 31-day period suggesting that the filter was blocked by the adhesive.  Devices F 
and H showed a rapid release in the first 10 days followed by a steady release in the next 
21 days.  The rapid release could be associated with leaking around the membrane or in 
other locations on the device.  The slowing release over time in these two devices might 
due to the lack of Dextran stored in the device for later release and is expected for high 
release devices.  Device G showed a burst release and then a release rate lower than the 





Figure 16 Cumulative Dextran release percentage for the devices with filter membrane 
or the porosity of the filter is less than anticipated in the model.  The drug delivery 
devices are designed to generate a steady release over at least 1 month.  Figure 17 shows 
the relative release rate for each device over time.  For the sealed devices (I-L), the 
release rate is near zero, as expected.  For the devices with four 40µm holes, all four 
devices (A-D) showed a higher rate between the 1st and the 5th day, and then the rate 
dropped to a level fairly consistent with model predictions.  The membrane (Devices E-H) 
generally showed a higher release rate, except for the devices that were completely or 
partially blocked.  Overall, the membrane devices showed the most variation both within 
a single device and between devices.   
Figure 18 shows a picture of devices A and F, respectively, after the 31 day 
experiment.  The darker color of device A confirmed that a relatively high amount of 
Dextran is still available in this device (potentially 96% of the Dextran remained).  Thus, 
both types of systems the PDMS device with diffusion holes should be able to deliver 























Overall, PDMS drug devices with diffusion holes shows a higher degree of 
consistency compared to PDMS devices with filters, because the coefficient of variation 
for the former is 0.41, which is half of the one for the latter of 0.84 over the 31-day 
period.  These results indicate that the PDMS devices with diffusion holes achieved more  
showed that they could release drug over time and at a steady rate once initial burst 
effects are allowed to finish. 
 
Figure 17 Average daily Dextran delivery (in percentage) over the 31-day period 
 
Figure 18 Image of devices A (top) and F (bottom) after 31-day release.  This image 
shows the relative difference in Dextran remaining, with 96% of the Dextran still 
available in device A, and about 40% of the Dextran available in device F.  The lighter 































Several prototype drug delivery devices for use in nerve regeneration were 
designed, fabricated, tested and characterized to deliver drugs of interest over time.  The 
inconsistent release data for the filter-based PDMS devices used in both NGF and 
Dextran release studies as well as the consistent release of the diffusion hole-based 
PDMS device in the Dextran release study suggested that using diffusion holes rather 
than an adhered membrane would be a better approach.  In the 31-day Dextran release 
study, all of the controls acted as expected, showing that the release occurs by the desired 
route – either through the PES filter membrane or four 40µm diffusion holes and the 
inner conduit, validating the general drug delivery approach.  A model based on Fick’s 
First Law of Diffusion was used to predict the release from the various devices and 
diffusion hole-based PDMS devices (devices A-D) in the Dextran study.  The model 
results were generally in the same range as the experimentally measured values, but there 
was significant variation both in rate and overall release for the experimental devices, so 
the appropriateness of the model is only generally confirmed.  Nevertheless, the model is 
likely valuable for designing future diffusion hole sizes and drug dosages to fit various 
applications.  In future work, a biodegradable conduit will be developed and designed 
based on the model and methods introduced in this paper.  Biodegradable materials 
should better suit the desired in situ application. 
 
 CHAPTER 4 
BRIDGING PERIPHERAL NERVE GAPS USING NGF-LOADED PLGA  
NERVE CONDUITS FOR NERVE REGENERATION 
Introduction 
Traumatic injury to peripheral nerves often leads to loss of motor control or 
sensation in the extremities if the severed axons on the proximal nerve stump do not 
regenerate and cross the nerve gap quickly [121].  For peripheral nerve gaps greater than 
10mm, special bridging techniques are required to encourage nerve regrowth in the 
proper direction, and currently either autografts or nerve conduits are used.  About 87.4% 
of upper limb nerve injuries can be repaired by end-to-end approximation, while 1.8% of 
upper limb nerve injuries require grafts or other forms of bridge to connect the two nerve 
stumps [53].  For those requiring bridging techniques, nerve autografts are the gold 
standard, but have some limitations, such as donor site deficits in muscle control and 
sensation [54].  Because short nerve conduits and autografts can achieve similar 
functional outcomes and regeneration results [57], use of nerve conduits to repair 
peripheral nerve gaps in a variety of anatomical locations is preferred when feasible [58].   
A variety of nerve conduits have been fabricated using a range of materials, 
coatings, and impregnated drugs.  Biodegradable materials have the advantage over non-
biodegradable materials of being eliminated naturally once their function is no longer 
needed.  Some nerve bridges provide not only guidance for axonal regrowth but also 




regeneration [52].  Nerve conduits loaded with either transplanted cells such as Schwann 
cells [80], stem cells [91], [122] or axon-growth promoting proteins, such as vascular 
endothelial growth factor (VEGF) [123] or nerve growth factor (NGF) [78], [93], [95], 
[124], typically show better axon growth.  NGF has been found to be particularly helpful 
because not only are fewer adverse effects observed when using NGF compared to other 
nerve stimulating proteins or cells [57], but also because denser axon branches are 
observed in chick dorsal root ganglia (DRG) cells when treated with NGF compared to 
glial cell line-derived neurotrophic factor (GDNF) [93], [94].  Research has also shown 
that locally delivered NGF can accelerate sciatic nerve regeneration [95]–[97].   
Combining the ability of a synthetic nerve conduit to direct nerve growth and 
NGF’s ability to encourage axon growth while exhibiting a reduced adverse response 
[57], is a known way to improve nerve regeneration.  Building upon this success, in this 
paper, we propose a novel biodegradable nerve conduit with a surrounding drug delivery 
reservoir for treatment of significant peripheral nerve injuries.  The proposed device is 
made of biodegradable PLGA and the drug reservoir is filled with NGF that can access 
the lumen of the nerve conduit through a diffusion membrane, as shown in Figure 19.  
The expected benefit of the drug reservoir is that a single device design can be used to 
deliver a variety of drugs to the lumen of the nerve conduit (the space between the inner 
and outer tubes in Figure 20) without needing to reengineer the entire system for each 
drug of interest.  The delivery rate of the device should be predictable for any drug, as 
drug diffusion through membranes is well understood, unlike microsphere-based PLGA 
applications [88], [89], [118], [125], [126] which depend on PLGA degradation rates.   





Figure 19 Schematic diagram of a PLGA nerve conduit.  Drug (NGF) loaded in the space 
between the outer and inner tubes will diffuse through the filter and enter the lumen of 
the inner tube, contacting nerve stumps and stimulating axon growth on the proximal 
nerve stump.  The inner tube can hold the two nerve stumps and guide the new-grown 
axon to meet the distal nerve stump.  Silicone sealant and a PDMS plug are used to seal 





Figure 20 A scanning electron microscope image of the transverse cross-sectional view of 
the PLGA nerve conduit.  The filter is attached on a window on the inner tube to allow 
the drug (not shown) stored between the inner tube and the outer tube to release into the 





at a steady rate to a nerve conduit.   
Materials and Methods 
Drug delivery devices made of PLGA were fabricated and the drug release filters 
attached to the inner tube.  Several tests were proposed to verify the function (drug 
delivery rate, bioactivity of the drug, and biocompatibility of the device) of the proposed 
device.  A diffusion chamber study was conducted to see if NGF can be released from the 
device.  Different combinations of NGF in polyvinyl alcohol (PVA) were also tested as 
PVA can help control the drug release [103] by partially blocking the pores on the filter 
and slowing NGF diffusion.  The experiments lasted 25 days, as that should be sufficient 
for the nerve to grow the length of the 10mm nerve gap, as previous studies have shown 
that the ulnar and median nerve regrow an average of 1mm/day in monkeys [58].  The 
bioactivity of the drug (NGF) was tested using chick dorsal root ganglion (DRG) cells 
[127] treated with media released from the proposed device at different time points. 
Mouse models were also used to test the biocompatibility of the device, as the dimension 
of mouse sciatic nerve is similar to human digital nerve.  The details of these experiments 
follow.  
Design 
The overall concept of the nerve regeneration device is to use a physical bridging 
technique with the aid of NGF to stimulate rapid repair of peripheral nerve gaps.  A 
previous study by our group has reported the release of bovine serum albumin (BSA) 
across a polyethersulfone (PES) filter into the lumen of a nerve conduit with the BSA 
stored in the space between concentric tubes  [55].  Another preliminary study showed 




In this paper, a similar PLGA device is used to deliver NGF.  The device is 
fabricated using 75:25 polylactic acid (PLA) to poly-co-glycolic-acid (PGA) copolymer 
ratio instead of 65:35 PLGA to increase the half-life of the PLGA degradation slightly.  
The PLGA was used to form the outer and inner tubes of the PLGA nerve conduit.  A 
PES filter membrane, a PDMS plug and some silicone sealant were also used to fabricate 
the nerve conduit.  Figure 19 illustrates the design of the nerve conduit in which the drug 
(NGF) stored in the space between two concentric tubes is released into the lumen of the 
inner tube through the filter, as shown in Figure 20, and thus is available to the proximal 
nerve stump.  Axon growth is expected to be constrained by the inner tube to meet the 
distal nerve stump, and the NGF should accelerate the nerve regeneration process.   
Device Fabrication 
Both the PLGA inner and outer tubes for the device shown in Figure 19 were 
fabricated from a PLGA emulsion in acetone and ethanol by solvent diffusion [128] and 
precipitation polymerization [129], respectively.  First, the PLGA emulsion was prepared 
by completely dissolving 10g PLGA (7525 DLG 7E, Evonik) in 20mL acetone with 
constant stirring at 44ºC on a hot plate.  Then, 6mL of ethanol was added into the PLGA 
emulsion at the same stirring rate and temperature until the emulsion turned transparent.   
To fabricate the inner tube, 200µL glass calibrated micropipets (2-000-200, 
Drummond Scientific) were used with the aid of a plastic bulb to suck the PLGA 
emulsion into the micropipets, coating the walls.  The micropipets with PLGA emulsion 
inside were then frozen overnight, and placed horizontally in a chemical hood for 10 days 
in order to remove the residual acetone and ethanol, leaving only a thin PLGA wall 




additional day to harden the PLGA. The PLGA inner tubes were then obtained by 
breaking these micropipets and removing the glass.  A carbon dioxide laser machining 
tool (VLS3.60, Universal Laser Systems) was used to generate a 0.8mm X 0.2mm 
window and trim the inner conduit into 15mm long pieces.  A 2.5mm X 0.8mm PES filter 
membrane (PES0032005, SterliTech) was attached to the window of the inner conduit by 
instant adhesive (4011, Loctite).   
For the outer tube, 1/8” Teflon rods were dipped in the PLGA emulsion, and 
immediately immersed in distilled water to form a thin layer of PLGA covering the 
outside of the Teflon rod.  The outer tube was then peeled from the Teflon rods by hand, 
and a blade was used to cut the outer tube into 7mm long pieces. 
For assembly, the outer tubes were placed around the inner tubes and the gaps filled 
by a PDMS plug that both secured and aligned the inner tube to the outer tube.  The 
PDMS plugs were made of a 10:1 ratio of PDMS to curing agent [55] and a biopsy punch 
was used to trim the PDMS pieces into plugs. RTV silicone sealant (734 flowable sealant, 
Dow Corning) was used to seal the ends of the conduit around the PDMS plug. 
After the nerve conduit was made, a radio frequency glow discharge (RFGD, 
commercially known as STERRAD, University of Utah Healthcare) was used to sterilize 
the device [130] before starting the release or biocompatibility tests.   
Release Test Protocol 
Samples and Controls 
An average drug delivery rate of at least 2ng/day release is desired as determined 
by a review of the NGF literature.  While different values of optimal NGF concentration 




DRG cells was shown to be optimal [93] while a 80ng/day NGF daily delivery rate for 
adult male Lewis rats [96] was shown to generate optimal nerve recovery.  In addition, 
the literature showed that optimal dosage may vary according to different goals 
(concentration or delivery rate) or verification methods (ex vivo or in vivo) used.  To meet 
these general goals, NGF in a concentration of either 0.05 or 0.1mg/mL with PVA at 
either 25 or 12.5mg/mL [41] was filled in the PLGA nerve conduits for the release tests.  
The hypothesis is that the device with the highest concentration of NGF and the lowest 
concentration of PVA will result in the highest NGF release, and vice versa.  A relatively 
low NGF release is also expected for the device without PES filter (the diffusion window) 
compared to all other groups.   
To minimize contamination, the sterilized PLGA conduits were filled with a 
selected combination of PVA and NGF right before starting the release test.  The drug 
was prepared by dissolving 0.1 mg lyophilized NGF (N2513, Sigma-Aldrich) in 0.5mL 
PBS with 0.1% BSA to form a 0.2mg/mL stock NGF solution.  A 50mg/mL PVA 
solution was prepared by dissolving PVA powder (363103, Sigma-Aldrich) in distilled 
water, and the solution was filtered through a 0.22µm filter.  The serial dilution of stock 
NGF solution with 50mg/mL PVA solution and PBS formed the desired combination and 
was filled into either the devices or the controls.  Device experiments were performed in 
triplicate, and the combination of NGF with either 0.1mg/mL or 0.05mg/mL and PVA at 
either 25mg/mL or 12.5mg/mL was filled into each PLGA nerve conduit (device), as 
shown in Table 8.  For the controls, a no PVA test filled with only 0.05mg/mL NGF 
without PVA was performed to determine the impact of PVA on NGF release in the 




Table 8 NGF and PVA dosage in the devices and controls for NGF release test 




Drug volume (µL) Max. NGF 
amount (ng) 
Device 1 0.1 25 26 2600 
Device 2 0.1 25 32 3200 
Device 3 0.1 25 25 2500 
Device 4 0.1 12.5 26 3600 
Device 5 0.1 12.5 18 1800 
Device 6 0.1 12.5 28 2800 
Device 7 0.05 25 25 1250 
Device 8 0.05 25 22 1100 
Device 9 0.05 25 27 1350 
Device 10 0.05 12.5 27 1350 
Device 11 0.05 12.5 20 1000 
Device 12 0.05 12.5 30 1500 
No PVA test 0.05 n/a 16 800 
Leakage test 0.1 25 25 2500 
either the window on the inner tube or the PES filter membrane, so that no NGF release is 
expected.  The positive controls consisted of 40 µL of 0.1mg/mL NGF in a 25mg/mL 
PVA solution in a 4mL receiver chamber filled with media.  The negative controls were 
4mL receiver chambers filled with media only.   
Receiver Chamber 
For both devices and controls, Dulbecco's modiﬁed Eagle's medium (DMEM, 
SH3026101, Thermo Scientific) with 10% fetal bovine serum (FBS, SH3091003, Thermo 
Scientific) was used as the medium for the receiver chamber.  This solution was used so 
that the media from the receiver chamber could be directly used to treat DRG cells in 
order to verify the bioactivity of the NGF used in the experiment.  Fifty mm 






Each PLGA nerve conduit was filled with the desired drug, as shown in Table 8, 
and sealed using the PDMS plug with silicone sealant.  The device was dried for 1 hour 
and then mounted individually onto the bottom of the Petri dish using silicone sealant.  
Thirty minutes was added to ensure the silicone sealant was dry before the application of 
the media to the receiver chamber.  After applying 3mL DMEM with 10% FBS into each 
dish, the Petri dishes were transferred into a 37ºC incubator.  Media samples in the 
receiver chambers for both devices and controls were collected after 1, 4, 14, 25, 117, 
254, 351, 480 and 600 hours.  For the experiments listed in Table 8, all the media in the 
receiver chamber was replaced with fresh DMEM with 10% FBS (sink method) so that 
data on all the NGF released into the receiver chamber in each period could be obtained.  
In addition, 500µL of sample were collected each time from the positive control without 
replacing the media.  An NGF ELISA kit (ab100757, ABCam) was used to analyze the 
NGF concentration at each time point for both devices and controls.   
NGF Bioactivity Test with DRG cells 
In order to verify the bioactivity of NGF released from the conduits over an 
extended period of time, especially the last period of the release study, a bioactivity test 
was performed in which the media from the receiver chambers of the release test with the 
highest cumulative percentage of NGF released in the 20-day period would be used to 








 hour collections from the 
release test were used to verify and compare the bioactivity of NGF during the first 20-
day period of the 25-day release test.  In addition to the devices, a 0-5ng/mL NGF dosage 




treating DRG with freshly prepared NGF solution with the released NGF media.  Both 
the standards (dosage curve) and media from the devices were plated on laminin-coated 
microplates (BioCoat, 35488, BD Medical) and incubated for 72 hours in a 37ºC 
incubator.  A methanol fixation process was applied on the plate to stop further growth of 
axons after the 72 hour incubation.  Rabbit beta-Tubulin (ab6046, ABCam) was used as 
the primary antibody, and Alexa Fluor 568 donkey anti-rabbit IgG antibody (A10042, 
Life Technologies) as the secondary antibody.  After the primary antibody binds to the 
axon and the secondary antibody stains the axon, 4',6-diamidino-2-phenylindole (DAPI, 
D1306, Life Technologies) was used to stain the cell body of the DRG cells in order for 
us to distinguish the axons from the cell bodies in the image.  Manual measurement was 
performed using Image J to calculate the axon growth in DRG cells outside of the cell 
body after the image was taken through a fluorescence microscope.  Axonal outgrowth 
length shorter than twice the cell body’s length was neglected because we assumed the 
axon was wrapped together in this case.   
Pilot Biocompatibility Animal Study 
A 3 week biocompatibility study in mice was performed.  Before implantation, the 
PLGA inner tubes were first trimmed to 5mm in length and sterilized by STERRAD 
[130], [131].  Then, these tubes were used to bridge 5mm gaps created on the right sciatic 
nerve of 3-month-old Sprague Dawley male mice (n=3).  A 140µm suture was used to 
suture the device to the sciatic nerve at both ends, and a polypropylene suture was used to 
suture the muscles, followed by a silk suture to suture the skin.  Animals were sacrificed 





Results and Discussion 
The PLGA devices were successfully fabricated and tested.  Details on the results 
of several of the experiments follow. 
Device Fabrication  
More than 30 devices were fabricated and tested in various ways.  No obvious 
leakage of the device was noticed when filling the reservoir chambers of the nerve 
conduit with NGF.  However, the drug reservoir volume was observed to be less than 
designed when filling the device with a calibrated syringe.  An average of 24.8µL drug 
reservoir volume was found in the devices and controls used in the release test compared 
to the designed 34.2µL drug reservoir volume.  The loss of volume in the reservoir 
chamber is likely due to the sterilization process as shrinkage has been shown to occur for 
PLGA devices [130].  Even with the reduction in reservoir volumes, these devices have 
enough space to store the desired volumes and concentrations of drug.   
NGF Release Results 
Figure 21 shows the cumulative NGF amount released from each PLGA device into 
the receiver chamber (Petri dish) at a series of time points according to the ELISA 
readings.  Many of the devices demonstrated a “burst effect” where a large amount of 
drug was released in the first day before settling into a steady release rate, which will be 
explored more later.  As can been seen in Figure 21, some of the experiments had to be 
stopped early due to fungal contamination developing in the receiver chamber (the Petri 
dish) as early as the day 10 collection, and the ones with contamination were discarded 
without measurement.  Therefore, the number of data points for the device samples and 
controls varied, and only two devices had data for the 25
th




controls had data for the 25
th
 day collection.   
Since all the media in the receiver chamber was replaced with fresh media during 
each collection, concentration data measured using the NGF ELISA were converted into 
NGF mass (ng) and the results were summed over time.   
The release data can be also represented in the cumulative percentage of NGF released 
into the receiver chamber at each time point.  The cumulative percentage of NGF release 
was obtained by dividing the cumulative NGF weight by initial NGF weight in the 
release chamber.  The results show that most devices still had more than 50% of the NGF 
left at the end of the study, and a constant positive release for all the devices indicates 
 
Figure 21 Cumulative NGF amount released into the receiver chamber.  In each 
collection, all the media in the receiver chamber was replaced with fresh media.  Thus, 
the sum of NGF concentration detected in each collection was shown in this figure to 
present the cumulative amount of NGF released from the PLGA device at each time 
point.  Concentration of  NGF and PVA filled in each devices: devices 1-3: 0.1mg/mL 
NGF in 25mg/mL PVA; devices 4-6: 0.1mg/mL NGF in 12.5mg/mL PVA; devices 7-9: 





that the PLGA device can continuously supply NGF even after the 25-day period.  Thus, 
the device as currently designed has the potential to fit clinical applications where a 2 to 3 
month consistent release is preferred.  The slopes for the data in Figure 22 are different 
than the ones in Figure 21 because different volumes and concentrations of NGF – shown 
in Table 8 – were filled into the devices and controls.  Figure 23 shows NGF daily 
delivery for the four designs (four combinations of NGF and PVA concentrations) in 
which cumulative NGF amount released between each collection time points were 
divided by the time period.  Devices 4, 7 and 9 were excluded from this figure due to 
their extremely low NGF release.  In Figure 23, devices prepared with the same 
conditions were averaged.   
 







Figure 23 NGF release rate comparison.  Plotted data are for the average of results for the 
same design (same concentrations of NGF and PVA).  Devices 4, 7 and 9 were excluded 
from these results due to their extremely low NGF release levels.  (a) All data. (b) 
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Devices 1-3, with 0.1mg/mL NGF in 25mg/mL PVA, showed a similar NGF 
release in the 15-day period with a cumulative NGF release ranging from 500 to 566ng, 
as shown in Figure 21.  The figure also shows that a cumulative NGF release percentage 
of 16 to 22 for the 15-day period.  They possessed a much higher (1468ng/day) release in 
the beginning, as shown in Figure 23, then the NGF release rate dropped to 4.5ng/day in 
the period between the 15
th
 and the 20
th
 day.  Though a higher initial release rate was 
observed, which is not necessarily detrimental, they showed a release rate higher than the 
2ng/day in the later stages of the release test, which was the minimum release rate desired.   
Devices 4-6, with 0.1mg/mL NGF and 12.5mg/mL PVA, showed a wide range of 
NGF release percentage and release rate.  Device 4 showed almost no release with only 
13ng cumulative NGF released from this device in a 25-day period, while device 5 and 
device 6 show a 207ng and 431ng cumulative NGF release in the first 15 days, 
respectively.  Due to the low release of device 4, the average daily NGF delivery rate of 
devices 4-6 is lower than one of the devices 1-3, though devices 4-6 have less PVA and 
tend to release faster than higher-PVA-concentrated devices 1-3 by design.  The most 
likely cause of the variation among devices 4-6 is the amount and location of the adhesive 
applied on the filter, which was difficult to control, and the size of diffusion window 
varied between devices.   
Devices 7-9, with 0.05mg/mL NGF and 25mg/mL PVA, also showed a different 
NGF amount, release percentage and release rate.  Only device 8 continued to release a 
reasonable amount of NGF in the given period, and ended with a 458ng cumulative NGF 
release in the first 10 days.  Devices 7 and 9 have a small release, and thus the average of 




devices 7 and 9 is likely to be the same as device 4, i.e., the filter of devices 7 and 9 were 
blocked by the adhesive and these devices only deliver less than 21ng NGF cumulatively 
in the release test.  The lower release rate of devices 7-9 (started with 0.05mg/mL NGF in 
25mg/mL PVA) compared to devices 1-3 (started with 0.1mg/mL NGF in 25mg/mL PVA) 
meets the hypothesis that lower given NGF concentration will lead to slower NGF release, 
although the release rate for the same design (devices 7-9) varied due to diffusion 
window size difference, which will be improved in the future.  
Devices 10-12, with 0.05mg/mL NGF and 12.5mg/mL PVA, showed relatively 
consistent release kinetics.  Devices 10-12 possessed the highest NGF delivery rate in the 
first 4 hours with the rate of 2295ng/day.  The NGF delivery rate dropped to a 3.1ng/day 
for the period between the 15
th
 and the 20
th
 day, and a delivery rate of 1ng/day in the 
period between the 20
th
 day and the 25
th
 day, indicating that this combination of NGF and 
PVA can achieve the desired NGF delivery rate of more than 2ng/day in the first 20-days, 
while still releasing drug, but at a lower rate, in the following 5-day period.   
Other than devices 4, 5, 7 and 9, all devices exhibited a two-step release in which a 
burst release (average of 286.8ng/day NGF release) was observed in the first day (25 
hours), while a slower release was observed for the remaining period.  This burst effect 
might be due to excess NGF that was left on the device when filling, though the devices 
were washed several times.  There is also the potential that during filling, or between the 
fill time and the beginning of the experiment, that drug was released or flowed into the 
inner conduit only to then be released when placed in the receiver chamber.  This excess 
NGF was then washed away after replacing the media of the receiver chamber several 




For the controls, the negative control performed as expected with a very low 
measure of NGF.  For the leakage test, 17.1% of NGF was released from its PLGA 
device, showing that the device was not totally sealed.  Although the release percentage 
from this leakage test is smaller than half of the devices, it still possesses a “release,” and 
thus a more careful fabrication process needs to be employed to ensure the sealing of the 
device.  The no PVA test showed the highest NGF release with a 455ng cumulative NGF 
released into the receiver chamber in a 10-day period.  When converting to percentage 
release, 56.9% of NGF was released into the receiver chamber in the 10-day period, 
confirming that the absence of PVA would allow for more rapid NGF release.   
The hypotheses of different PVA and NGF concentration filled in the device are 
that high PVA will result in low NGF release, and high NGF will result in high NGF 
release.  Within the same given PVA concentration, devices 1-3 (with 0.1mg/mL NGF) 
have a higher NGF release rate compared to devices 7-9 (with 0.05mg/mL NGF), which 
fits the expectation.  Devices 4-6 (with 0.1mg/mL NGF) also have a higher NGF release 
rate compared to devices 10-12 (with 0.05mg/mL NGF), which also fits the expectation.  
On the other hand, within the same given NGF concentration, devices 1-3 (with 
25mg/mL PVA) have higher NGF release rate compared to devices 4-6 (with 12.5mg/mL 
PVA), which does not fit the expectation.  The extremely low release of devices 4 and 6 
affect the average release rate in devices 4-6.  For the devices and control filled with the 
same 0.05mg/mL NGF, no PVA test (with 0mg/mL PVA) has the highest NGF release 
rate compared to devices 7-9 (with 25mg/mL PVA) and devices 10-12 (with 12.5mg/mL 
PVA).  Devices 10-12 also show a higher NGF release rate compared to devices 7-9.  




release.   
Both the positive control and the negative control met expectations and set a 103ng 
and 6ng cumulative NGF release boundary for the devices; all measurements for devices 
and controls fell between these values.  Though the leakage test did indicate some 
leakage for that device, some devices (such as devices 4, 7 and 9) showed nearly zero 
release (but still greater than negative control) and indicate the devices can be sealed 
effectively – even if that was not the goal for these particular devices.  Overall, the results 
suggest that both the device and the drug concentrations with PVA can be used to release 
drug in a useful range.   
Bioactivity Test in DRG cells 
Since it was now known that NGF could be released at a desired rate, the next 
question revolved around the activity of the NGF after being stored in the device and then 
being released after an extended period of time. The media collected on day 20 from the 
release tests was delivered to DRG cells to determine if the NGF would still encourage 
DRG neurite growth. 
To provide a reference for these tests, a NGF dosage curve with 0-5ng/mL of NGF 
on DRG cells, as shown in Figure 24, showed that a maximum average axonal outgrowth 
of 92µm was reached for these DRG cells when the NGF concentration in the treatment 
was no less than 1.25ng/mL.  The NGF released from device 2 and device 10 was chosen 
for these experiments, as the average 20-day NGF release was more than 2ng/day.  The 
results for device 2 are shown in Figure 25.  Overall, the results showed that the NGF still 
retained some bioactivity.  Surprisingly, all the DRG cells died when treated with the 1
st
-





Figure 24 NGF dosage curve on DRG cells.  Treatments of 0-5ng/mL NGF were applied 
to suspended chick DRG cells for 72 hours to obtain the axonal outgrowth length 
generated by different NGF concentration.  This figure shows that at a 1.25ng/mL NGF 
concentration, axonal outgrowth reaches a maximum of 96.5µm.  In the fluorescence 
pictures, the color purple represents the cell body of the DRG cells, and the color red 














 hour medium from the receiver chamber of device 2 were applied to chick DRG 
cells for 72 hours in order to verify the bioactivity of NGF in these treatments.  This 
figure shows that no signal (DRG) could be observed in the 1
st
 hour treatment and some 
signals for the latter treatments, indicating that the NGF in the latter treatments was 




treatment was yellow, unlike the treatment’s usual color (pink) suggesting that the media 
for this particular experiment had gone bad for some unknown reason.  Later 
investigation found that the cells were killed due to the presence of uncured silicone 
sealant releasing acids.  As the silicone had cured or the acids removed before the later 
experiments, the results for them were significantly better. The 25
th
-hour collection 





-hour collections of device 2 showed an 80.4µm and a 76.6µm axonal 
outgrowth with respect to a 32.3ng/mL and a 23ng/mL NGF concentration, respectively.  
All of these concentrations were well above those used for our reference experiments, so 
direct comparison is not possible, but it is known that there is an optimal NGF 
concentration, as can be seen in Figure 24, and that excess NGF can lead to slightly 
reduced outgrowth, as appears to be the case here.  In any case, the growth associated 
with the NGF released from device 2 is repeatably above the no NGF growth, indicating 
that the released NGF still has some bioactivity. 
Device 10 also showed positive results for NGF bioactivity, as shown in Figure 26.  
In contrast to the results for device 2, the treatment from the 1
st
-hour collection in device 
10, resulted in a 41.1µm axonal outgrowth with respect to a 19ng/mL NGF concentration, 
which, while still being lower than the no NGF control, did not kill the cells.  
Nevertheless, it is likely that the silicone sealant contamination likely stunted the growth 
of the axons on these DRG cells, as later tests showed much better results.  The 






-hour collections showed a 75.8µm, a 95.7µm 
and a 89.1µm axonal outgrowth with respect to a31.9ng/mL, a 26.3ng/mL and a 




the device in this period can promote the maximum axon growth in chick DRG cells, and 
the results from this device are closer to the optimal results obtained from our reference 
experiments.  For the NGF released between the 351
st
 and the 480
th
 hour, it could still 
result in an average of 89.1µm axonal outgrowth, which demonstrates that the nerve 
regeneration device is capable of delivering bioactive NGF for the 20-day period. 
Pilot Animal Study Biocompatibility Test  
A demonstration PLGA device was implanted in 3 mice for a period of 3 weeks.  
After the 3 weeks, the observed inflammatory response was similar to that for areas 
where no device was placed as shown in Figure 27.  These results give a preliminary 
indication that the device would not cause any significant inflammatory or 
biocompatibility issues over the relevant time frame for nerve regrowth through the 
 









 hour media from the receiver chamber of device 2 were applied to chick DRG cells 
for 72 hours in order to verify the bioactivity of NGF in these treatments.  This figure 
shows a relatively low bioactivity of NGF in the 1
st
 hour medium with only 41.1µm 





media, followed by a drop at the 480
th
 hour medium.  At the 117
th
 hour medium, axonal 





conduit.  The results also suggest that the sterilization technique was effective.   
Conclusion 
The proposed PLGA nerve conduit with either 0.1mg/mL NGF in 25mg/mL PVA 
or 0.05mg/mL NGF in 12.5mg/mL PVA stored in a drug reservoir can constantly deliver 
bioactive NGF for a 25-day period to the nerve regeneration conduit.  The released NGF 
promoted nearly maximal axonal outgrowth when applied to chick DRG cells.  
Preliminary implant results suggested that the device would be biocompatible over the at 
least the first 3 weeks of implantation.  Nine out of 12 tested devices possessed an 
average NGF delivery rate of more than the goal of 2ng/day.  It also showed that every 
combination of NGF and PVA tested can result in a daily NGF delivery rate of more than 
2ng/day for most of the 25-day period tested.  Most of the average NGF release rate 
results from different PVA and NGF combination fit the assumption of higher NGF and 
 
Figure 27 Three week biocompatibility study of inner tube in mice: after the surgery (left) 




lower PVA will lead to a faster NGF release.  Several lessons were also learned about the 
fabrication and testing of the devices.  For example, it was learned that the adhesive 
application process to attached the filters to the inner conduits needs to be improved, as 
some devices delivered almost no NGF due to membrane clogging.  In the future, a 
complete biodegradable device that eliminates the use of the PES filter membrane will be 
tested in order to avoid any blockage of the diffusion window by adhesive.  Also, a more 
careful filling process will be conducted to eliminate the presence of any air bubbles in 
the device.  A longer animal study will also be conducted to see if injured peripheral 
nerves can recover and innervate distal muscles.  More thorough verification protocols 
will be used to analyze the animal test result, including histology and walking track 
analysis.   
 CHAPTER 5 
NERVE CONDUIT SUPPLEMENTARY DATA 
Several designs and experiments of nerve conduits have been proposed and 
conducted for peripheral nerve regeneration.  In this chapter, release studies using either 
PDMS or PLGA nerve conduits with different proteins will be discussed, followed by 
modeling to design future complete PLGA devices.   
A 5-day Basic VEGF Release Study from PDMS Nerve Conduit 
Design and Materials 
Prototypes of nerve conduits made of PDMS were first used to demonstrate 
possible drug release from a drug reservoir through a semipermeable membrane into a 
receiver chamber without any nerve conduit.  These PDMS devices were made thin and 
designed to occupy the smallest space possible, simulating the size anticipated for future 
in vivo experiments.  VEGF was chosen and loaded into this prototype due to its ability to 
promote axonal outgrowth [114].   
PDMS was chosen to form the main structural layer of the drug reservoir due to its 
biocompatibility [105], [132]–[134], ease of use, and its ability to form nanoscaled 
structures.  Since a semiflexible structure was preferred, a ratio of 10:1 PDMS to curing 
agent (Sylgard 184 silicone elastomer base and curing agent, Dow Corning, Midland, MI) 
was used to prepare the PDMS layer, followed by a standard PDMS soft lithography 
process [135]–[137].  Polyethersulfone (PES) membranes (PES0032005, SterliTech, Kent, 




Two PDMS devices, as shown in Figure 28, were designed and fabricated in the 
same way in order to test the ability to deliver VEGF.  The dimensions of these PDMS 
prototypes measured 33mm by 11.5mm by 1 to 1.3mm.  Despite the difference in size of 
these prototypes, the volume of the drug reservoirs was fixed at 14.5µL with the same 
4mm by 3mm by 30µm filter membrane and 1.3mm diameter window.  
Fabrication 
The fabrication process of these PDMS devices can be divided into the fabrication 
of PDMS layers, preparation of the filter membrane and assembly of the whole device.  
Three layers of 160µm tape (Gerber 15 SM4 InstaChange tape, Regional Supply, 
Salt Lake City, UT) were cut into 12mm by 2mm pieces and attached to a Petri dish to 
serve as a mold for forming the reservoir part in the PDMS layer.  A 10:1 PDMS solution 
was prepared by mixing silicone elastomer base with its curing agent thoroughly and 
degassing to remove trapped air in the solution.  
This PDMS solution was then poured onto the Petri dish mold and cured at 67.5°C 
 
Figure 28 Photograph of the PDMS devices. Two PDMS devices serving as prototypes 
for demonstrating the ability to store and release drugs were designed and tested with 




for 4 hours.  A PDMS cover layer with a 1mm diameter hole, as shown in Figure 28 was 
cut to serve as the window for drug release.  The cured PDMS layers were then peeled 
out from the mold.  A PES filter membrane cut by a CO2 laser (VLS 3.60, Universal 
Laser Systems, Scottsdale, AZ) was sandwiched between the two PDMS layers, and air 
plasma was used to bond these two PDMS layers together [108].   
Test Setup 
Earlier experiments showed that these PDMS devices could deliver BSA for 1- and 
5-day periods.  Since the molecular weights of 56kDa BSA [138] and human 45kDa 
VEGF [139] are similar, the size of the BSA and human VEGF are likewise similar. The 
devices designed for running the BSA diffusion test were therefore tested with human 
VEGF to discover and confirm the result of human VEGF storage and diffusion across 
the device.  
Ten microgram10 µg of human VEGF lyophilized powder (8065SF, Cell Signaling, 
Danvers, MA) was first reconstituted to form the drug solution with 100µL 5% w/l 
polyvinyl alcohol (PVA, 363103, Sigma-Aldrich, St. Louis, MO) in phosphate buffered 
saline (PBS).  About 14.5µL of this VEGF solution was filled into the reservoir through a 
calibrated syringe, and then the PDMS device was placed into a 7mL glass amber vial 
filled with 4mL PBS, as shown in Figure 29.  Two sets of glass amber vials were used, 
i.e., two unknown samples were tested for their diffusion and release rate across the filter 
membrane to the receiver chamber.  These two vials were placed on an orbital shaker at 
room temperature, and samples were collected at 0.17, 7, 25, 47 and 109 hours after 
placing the PDMS devices into the glass amber vials.  The maximum VEGF 





Figure 29 Test setup for 5-day VEGF diffusion test. A PDMS device filled with 14.5uL 
10ug/mL VEGF was placed in the glass amber vial with 1mL PBS as the receiver 
chamber medium 
362.5µg/mL.  ELISA was designed to measure VEGF concentrations in the receiver 
chamber, and45 of the 96 wells of a human VEGF-A platinum ELISA kit (BMS277/2CE, 
eBioscience, San Diego, CA) were used for this experiment.  Samples were collected in 
triplicate, with duplicate positive calibration standards ranging from 0.078 to 5 pg/mL 
and duplicate negative standards. 
Results and Discussions 
Readings from the VEGF ELISA assay were plotted to generate VEGF release 
curves, as shown in Figure 30.  There was no calibrated VEGF concentration for this 
experiment due to the design error of the VEGF standards.  VEGF standards were 
prepared 100,000 less than the expected VEGF release region from the devices, thus the 





Figure 30 Cumulative 5-day VEGF reading.  Though unitless, both devices show near 
zero-order release over a 5-day period after a small initial burst 
Though no calibrated VEGF concentration was obtained from the reading due to 
the lower range of the VEGF standards, the cumulative reading for 5-day VEGF diffusion 
teststill had a positive slope and indicates the cumulative release of VEGF among the 
109-hour experiment time.  This indicates that these two PDMS devices, as shown in 
Figure 28, could consistently deliver VEGF from the drug reservoir into the receiver 
chamber, since the slope of the curve in Figure 30 is constant.  It also indicates that the 
PDMS device has the ability to store the drug, and constantly diffuse the drug into the 
environment.  Therefore, further experiments were performed in order to test the device’s 
ability to deliver the desired drug into the nerve conduit, which was used to bridge a 





A 6-day BSA Release Study from PDMS Nerve Conduit 
Introduction 
Almost 3% of trauma patients suffer from peripheral nerve injuries causing lifelong 
disturbances [49] in function and adverse socioeconomic consequences [46] due to the 
fact that these injuries are difficult to treat and have poor outcomes with contemporary 
treatments [45]. Peripheral nerve injuries caused by accidents or battlefield incidents with 
nerve gaps greater than 1-2cm require special bridging techniques [52]. Autologous nerve 
grafts are typically used to bridge the nerve gap; however, this requires additional surgery 
and can result in donor site deficits in function or sensation. Despite successful tension-
free re-approximation of severed nerve ends, outcomes are dismal primarily due to poor 
healing, scar formation and the slow rate of nerve regeneration.  
Several options have emerged to improve outcomes in peripheral nerve repair.  
These include artificial nerve grafts, cadaver grafts and nerve conduits.  Nerve conduits 
made with either synthetic or natural materials have been used to guide axons and bridge 
the nerve gaps ranging from 5 to 80mm [59]. For example, biodegradable polymer 
conduits embedded with Schwann cells showed a better result for nerve regeneration 
compared to autografts over a 6-week period in vivo [80]. Additionally, biodegradable 
polymer nerve conduits with NGF were tested for 3 months in vivo, showing significant 
NGF release in a 10-mm nerve gap in a rat sciatic nerve model [78]. In brief, VEGF [114], 






Design and Fabrication of the Nerve Conduit 
Design and Materials 
Prototypes of the nerve conduit were designed, fabricated, and tested to explore the 
possibility of drug delivery using concentric conduits with a semipermeable membrane. 
PDMS was chosen to form the main structural layer of the drug reservoir, i.e., the outer 
concentric tube, due to its biocompatibility [105], [132]–[134] and its ability to form 
nanoscaled structures. Ten to one PDMS to its curing agent (Sylgard 184 silicone 
elastomer base and curing agent, Dow Corning, Midland, MI) was used to acquire a 
relatively flexible PDMS structure. Pellets of thermoplastic PCU, purchased from DSM 
Biomedical, referred to as Bionate II, were heat extruded into tubes with outer and inner 
diameters of 1.5 and 1.3mm, respectively. Bionate II tubes show good biocompatibility 
and can be suitable for in vivo drug delivery. Biocompatible polyethersulfone membranes 
(PES0032005, SterliTech, Kent, WA) with 0.03µm pore size were attached to a window 
created in Bionate II tube in order to control drug diffusion.  Figure 19 shows the sagittal 
cross-sectional illustration of the nerve conduit. These conduits would be interposed 
between the cut ends of a nerve.  Once the drug diffuses from the reservoir via the filter, 
it will contact the axon growth cone and enhance axon number, diameter and density 
within the conduit and across the gap.  
A 12-mm-long PDMS outer conduit reservoir with a thinner 15-mm-long Bionate II 
tube was the prototype used to demonstrate diffusion across the polyethersulfone filter. 
The drug reservoir volume ranged between 50 to 100µL among the various prototypes. 
Drug release was controlled by selection of polyethersulfone membranes with different 




while the window size slightly varied from one device to another due to the flexible 
nature of Bionate II tubes.  
Fabrication 
Ten to one PDMS was prepared using standard methods of PDMS soft lithography 
[135], [136]. The PDMS solution was then poured into 1.5mL Eppendorf vials and baked 
at 65°C for 2 hours to form cylinders. A 5mm biopunch was used to create a hollow 
structure – the drug reservoir – in the PDMS outer conduits and the same tool with a 
1.5mm biopunch was used to form the outer PDMS plugs to seal and secure the Bionate 
II tube in the device, as shown in Figure 10.   
The Bionate II tubes prepared with a 1.4mm outer diameter and a 1.0mm inner 
diameter were used as the nerve conduit for in vitro drug release experiments. The tube 
was cut into 15mm sections and one hole with approximate 1-by-2.5-square millimeter 
dimension was punched at the center to serve as windows for the drug to diffuse into the 
tube. A polyethersulfone filter membrane was prepared in squares to cover the window 
and designed for the control of drug release. Loctite 4011 adhesive (18680, Loctite, 
Westlake, OH) was applied along the edge of the window to attach the polyethersulfone 
filter membrane without blocking the pores on the membrane.  
The Bionate II tube with the filter membrane secured was then placed in the lumen 
of the PDMS outer conduit. Small PDMS concentric plugs were prepared by punching a 
3mm-thick PDMS layer with 5mm and 1.5mm biopunches. They were then plugged into 
the Bionate II tube at both ends in order to form a drug reservoir in the lumen of the 
PDMS outer conduit. One end of the PDMS tube was sealed with this 3mm-thick PDMS 




into the reservoir through the other end of the PDMS outer conduit. In order to minimize 
bubbles, which lead to loss of diffusion area on the filter, the drug reservoir was filled 
completely. Therefore, the volume of drug ranged between 50 to 100µL. Next, the other 
side of the PDMS outer conduit was sealed with another PDMS plug, while RTV 734 
silicone sealant (2307774-1008, Dow Corning, Midland, MI) was applied instead of 
uncured PDMS, since it required no heating, which could have damage the drug. After 
the device was placed at room temperature for 15 minutes to cure the sealant, it was ready 
to use.   
Test and Results 
Test Setup 
The prototype test experiments utilized bovine serum albumin (BSA, A8022-500G, 
Sigma Life Science, St. Louis, MO) to demonstrate the diffusion across the device and 
the receiver chamber, which was a 7mL amber glass vial filled with 7mL of 1x phosphate 
buffered saline (PBS). The initial concentration of the BSA solution (serving as a drug 
simulant) was 100mg/mL and was prepared by vortexing 100mg of BSA powder into 
1mL PBS at room temperature for 3 minutes. Three unknown samples were tested along 
with three positive controls and two negative controls, as shown in Table 1. BSA 
standards (23209 and 23225, Thermo Scientific, Rockford, IL) were used to both prepare 
the positive standards between 2mg/mL to 10µg/mL and analyze the concentration on 
three microplates.  
For negative control 1 and samples 1, 2 and 3, the 6-day diffusion test started with 
filling the Bionate II tube (nerve conduit) with the desired drug, as shown in Table 9, then 




Table 9 Samples corresponding to drugs and receiver chambers 
Sample name Drug in the 
reservoir 
Maximum possible 
concentration in the 
receiver chamber 
Positive control 1 120µL BSA 1714.3µg/mL 
Positive control 2 80µL BSA 1142.9µg/mL 
Positive control 3 2µL BSA 28.6µg/mL 
Negative control 1 80µL PBS 0 
Negative control 2 n/a (no reservoir) 0 
Sample 1 50-80µL BSA 1142.9µg/mL 
Sample 2 80-100µL BSA 1428.6µg/mL 
Sample 3 75-80µL BSA 1142.9µg/mL 
the positive controls, on the other hand, the desired volume of BSA was filled directly 
into the 7mL of PBS inside the vial. For negative control 2, since no PDMS device was 
used, 80µL PBS was directly injected into the 7mL PBS in the vial. Multiple positive 
controls were used to not only serve as controls for different samples with different 
volumes of BSA, but also to provide readings in extremely small concentration value to 
better describe the situation when the diffusion rate was limited for some devices. 
Positive control 1, with 120µL BSA, could serve as the control for all three unknown 
samples, while positive control 2, with 80µL BSA, could serve as the control for sample 
2 and 3.   
All vials were placed on a vial holder that sat on an orbital shaker which smoothly 
mixed the medium in the vials. The purpose for filling the Bionate II tube with PBS 
before putting the device into the vial was to eliminate air bubbles which would impede 
the drug from diffusing out since the Polyethersulfone filter membrane was designed to 
deliver drugs from a solution into another and bubbles in contact with the filter 
membrane on the receiver chamber side would lead to no diffusion. The same reason also 




minimize bubbles in the receiver chamber, and therefore minimize the possibility of 
bubbles appearing in the Bionate II tube.   
Samples were collected after 0.5, 17, 46, 61, 91 and 112.5 hours in triplicate in 
three 96-well microplates.  Standards, on the other hand, were prepared in duplicate in 
each microplate and thus six copies of one standard were acquired.  Before collecting 
samples from vials, a 30 second vortex step was performed in order to mix the solution 
well.  The same volume of PBS was added into the receiver chamber every time after the 
same collection in order to maintain the same volume of the receiver chamber.  After 
collecting the last series of samples, 200µL of working reagent was then added in each 
well and we then followed the standard operation procedure provided by the assay maker 
for the BSA standard to perform plate reading at 562nm wavelength on a 
spectrophotometer.   
A follow up experiment was designed to determine the magnitude of the diffusion 
when incorporating a nerve conduit on the device. The similarity in molecular weight 
between 56kDa BSA [138] and human 45kDa VEGF [139] suggested that they could be 
used interchangeably for proof of concept, and both were much smaller than the 0.03µm 
pores on the filter membrane. Therefore, BSA was chosen due to its bigger size and 
slower diffusion, making it a worst case scenario. 
Results 
Readings from the spectrophotometer plate reader were analyzed and calibrated 
using Microsoft Excel.  The BSA concentration in the receiver chamber over the 6-day 
period is shown in Figure 31, and Figure 32 shows the percentage of BSA released into 





Figure 31 Six-day BSA release concentration (µg/mL) into the receiver chamber. Three 




Figure 32 Six-day BSA release percentage into the receiver chamber. Three positive 




were within specific ranges, the maximum possible BSA volume was used as the 
denominator, that is, 80µL for sample 1, 100µL for sample 2 and 80µL for sample 3.   
Though the BSA release percentage of positive control 1 in Figure 32 increased 
from 76 to 101% and that of positive control 2 increased from 82 to 106%, they were 
relatively flat compared to samples 1 and 2. The BSA release percentage of sample 2 
increased 23.6% between the 0.5 and 17
th
 hour, while the release from sample 3 increased 
from 27.6%. All the samples fall between positive control 1 and negative controls 1 and 2.   
Discussion 
In the BSA testing, after 61 hours of diffusion, the diffusion rates (the slope in 
Figure 32) of both sample 2 and 3 slowed down because the BSA concentration in the 
receiver chamber was higher and thus the diffusion gradient became lower. The diffusion 
rates for the first 61 hours were 0.68 and 0.85%/hr for sample 2 and sample 3, 
respectively. In comparison, the diffusion rates for the proceeding 51.5 hours were 0.19 
and 0.13%/hr for sample 2 and sample 3, respectively. 
Negative values of the BSA release percentage were generated from the negative 
concentration based on the calibration curve in which the standards were prepared 
between 0 to 2000µg/mL. Since the calibration equation was a linear function that fits 
most of the curve to achieve minimum standard deviation, the equation could not 
interpret the concentration in the region of lower concentration precisely and therefore 
lower concentrations than were possible were acquired for the same plate reading. If only 
the reading values of small concentration standards were used to generate the 
concentration calibration equation, the reading values of both negative controls 1 and 2 




were above the reading for 0 concentration standard.   
Last but not least, the BSA concentration increment of sample 1’s receiver chamber 
was about 27µg/mL during the 112.5 hours of diffusion based on the readings from lower 
concentration standards. Its diffusion rate was relatively low compared with samples 2 
and 3 probably because the filter was blocked. Either the Loctite 4011 adhesive from the 
fabrication process, or air bubbles in the drug reservoir blocked the filter; therefore, the 
drug could not diffuse out and release into the nerve conduit, diffusing into the receiver 
chamber. Though the filter was blocked in sample 1, it suggests that no or minor leakage 
was shown on this device since the drug would not leak into the receiver chamber.  
Conclusion and Future Work 
This work suggests that the prototypes for demonstrating the possibility of drug 
delivery across the filter membrane and release into the nerve conduit using BSA were 
successful and could be used for drug delivery at a reasonable release rate. VEGF and 
NGF will be used to explore the capability of the device followed by in vivo drug 
delivery test on rats.   
A 25-day Dextran Diffusion Study 
Design 
Similar to the 31-day Dextran diffusion study, this 25-day Dextran diffusion study 
was a pilot study to use Dextran to mimic the NGF release kinetics.   
Modeling 
The same model as the one shown in Chapter 3 was used to predict Dextran 




and after entering the parameters shown in Table 10, the concentrations in the receiver 












-day collection with 
sink method used are shown in Table 11.   
Three sets (n=4) of PDMS devices were proposed in order to verify both the 
integrity of the device and the consistent release in the same design.  Table 11 shows the 
modeling results for the Dextran concentration in the receiver chamber at different time 
point, with sink methods used for all three sets of the PDMS devices.  Similar to the 31-
day Dextran diffusion study in Chapter 3, PDMS devices with diffusion holes were 
expected to have consistent release kinetics compared to PDMS devices with PES filter  
Table 10 Known parameter for the model 
Description Notation Value  Unit 
Cross-sectional area in 
the inner conduit 
A1-2           m
2
 
Wall thickness of the 
inner conduit 
Δx0-1 100 µm 
Distance between the 
diffusion hole to the 
receiver chamber 
Δx1-2 10 mm 
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membrane.  No release was expected for the sealed device.   
In addition to these three sets of PDMS devices, two reference samples (n=1) with 
known concentrations of 2551ng/mL and 17847ng/mL Dextran in PBS were added into 
this study to compare the Dextran signal change for the expected 5-day net concentration 
from the modeling results of PDMS devices with diffusion holes and PDMS devices with 
filters, respectively.  Table 12 shows the volume and design for each device and reference 
samples used in this 25-day Dextran release study.  Seven mL PBS was filled into amber 
glass vials as the media for the receiver chamber.   
Fabrication 
The fabrication process of the PDMS devices is similar to the PDMS devices used 
in the 31-day Dextran diffusion study in Chapter 3.  Only the size of the through diffusion 





Table 12 PDMS devices and reference samples used in the 25-day Dextran release study 





Device A With two 50µm 
diffusion holes 
125 
Device B With two 50µm 
diffusion holes 
100 
Device C With two 50µm 
diffusion holes 
125 
Device D With two 50µm 
diffusion holes 
125 
Device E With filter 125 
Device F With filter 125 
Device G With filter 125 
Device H With filter 100 
Device I Without filters or 
holes 
175 
Device J Without filters or 
holes 
125 
Device K Without filters or 
holes 
125 
Device L Without filters or 
holes 
125 
Test Setup for Dextran Diffusion Experiments 
Table 11 shows the design and expected Dextran concentration in the receiver 
chamber in a 25-day period, and Table 12 shows the approximate volume of Dextran 
loaded into each device.  Twelve and a half mg/mL Dextran was prepared by dissolving 
25mg Dextran with PBS.  The setup of the diffusion chamber is the same as the ones in 
BSA and NGF release study, besides that the sink method would be used in which the 




collection.  Reference samples M and N have no PDMS devices, and Dextran of 10µL 
1.79mg/mL and 10µL 12.5mg/mL was directly added into 7mL PBS in the receiver 
chambers.  Unlike the device groups using the sink method, only two aliquots of 400µL 
samples will be collected from reference samples M and N each time, with no fresh PBS 
filled into the receiver chambers.  Samples were stored as the same manner shown in 
Chapter 3, and the plate would also be read with the same excitation and emission 
wavelengths shown in Chapter 3.   
Results and Discussion 
The reference samples M and N show a varying Dextran concentration in the 25-
day period, as shown in Figure 33.  For reference sample M, the concentration varies 
from1873ng/mL to 2537ng/mL, with a 14.1% standard deviation.  For reference sample 
N, the concentration increases from 18566ng/mL to 27051ng/mL, with a 16% standard 
deviation.  Due to the fact that the glass vials used in this 25-day Dextran release study 
was not new, though possible autoclave sterilization might be conducted before the use, it 
may contain some residual protein that can interact with Dextran.  Also, evaporation of 
PBS can contribute to the increasing concentration of the reference sample N.  For the 
reference sample M, the varying concentration may result from the liner of the amber vial  
 

















trapping some Dextran, since a thorough Vortex process was not taken in order to remain 
the same collection method as the sample groups.  For the device with two 50µm 
diffusion holes (devices A-D), a relatively consistent results were acquired when 
comparing to the modeling data, as shown in Figure 34.  Experimental data of devices B, 
C and D mostly fit the model.  Device A has an initial release, followed by a zero release.  
It is due to either air bubbles got introduced into the PCU conduit when replacing the 
media after collections, or the air bubble in the drug reservoir impedes the drug from 
diffusing through the 50µm holes.   
For PDMS device with filters, Figure 35 shows the experimental data comparing to 
the modeling result.  As observed in the previous 3-week NGF diffusion study, designs 
with filter as the diffusion window have inconsistent results due to the application of 
adhesive may partially or totally block the filter window and reduce its porosity.  For 
device F, though relatively similar results in the experimental and modeling data, it 
suggests that the filter is not securely attached to the PCU conduit because a porosity of 1 
was used in the modeling (which assumes that the filter is physically not in appearance).   
For PDMS device without filters or diffusion holes, Figure 36 shows the experimental 
data compared to the modeling result.  Only a minor signal of Dextran detected for 
devices I and L, and no further release of Dextran was detected for any devices with this 
design.  The minor signal of Dextran in devices I and L might result from initial Dextran 
filling process in which extra Dextran flowed out from the reservoir before the sealing 






Figure 34 Cumulative Dextran release percentage from the devices with diffusion holes.  





Figure 35 Cumulative Dextran release percentage from the devices with PES filter 
























































A 5-day Dextran Control Evaporation Study 
This 5-day Dextran control evaporation study shows that only a 5-day period can 
result in a huge Dextran concentration change under the current experimental setup.  
Table 13 shows the Dextran concentration variation in this 5-day study.  Two out of four 
controls have a more than 10% concentration change.  Table 14 also shows that a 2-7% 
mass loss was observed in this 5-day study.  Because the control with the higher mass 
loss did not result in a higher concentration change, this indicates that either the glass vial 
is not clean or the spacer in the cap of the glass vial traps some Dextran.   
A Dextran control evaporation study is also proposed in order to identify the effect 
of the evaporation of PBS in the receiver chamber resulting in a Dextran concentration 
change.  Two groups (n=2) of controls were used in this study in order to explain the 
Dextran concentration difference in the reference samples M and N in the 25-day Dextran 
diffusion study.  Controls MA and MB have the same content as the reference sample M 
shown in Table 12, and controls NA and NB have the same content as the reference 
sample N shown in Table 12.  Prior each collection, the whole receiver chamber (the 
amber glass vial) would be weighted in order to track the PBS loss due to evaporation.   
























MA 1757.6 1990.8 2551.0 1874.2 164.9 8.8 13.3 














Table 14 Mass (gram) loss of the receiver chamber (glass vial) in the 5-day Dextran 
control evaporation study 
Control number Day 0 mass Day 5 mass Mass change percentage 
MA 16.2 15.9 1.8 
MB 16.1 15.6 3.0 
NA 16.6 15.4 7.1 
NB 16.4 15.7 4.3 
A 7-day BSA Release Study from PLGA Nerve Conduit 
Introduction 
Peripheral nerve injuries affect about 3% of trauma patients and result in significant 
disturbances in their lives due to lost motor function and sensation.  For peripheral nerve 
injuries with gaps greater than 1-2cm, special bridging techniques are required for nerve 
repair [52]. Nerve autografts are the gold standard for repairing nerve gaps but these 
results in donor harvest site deficits.  Here, a synthetic nerve conduit with the potential 
for controlled and sustained drug delivery to improve nerve regeneration has been 
investigated.  Concentric nerve conduits made of PDMS was reported to deliver protein 
(BSA) for 6 days [55].  As an improvement, a biodegradable material was chosen in this 
work in order to minimize long-term incompatibility and need for subsequent device 
removal. BSA was used for proof of principle for assessing the ability of the device to 





Materials and Methods 
Inner (1.6mm diameter, 7mm long) and outer (3.2mm diameter, 17mm long) 
cylinders were fabricated from PLGA (LP-381, SurModics Pharmaceuticals) using glass 
capillary tubes and Teflon rods. A PES filter membrane (30nm pore size) (PES0032005, 
SterliTech, Kent, WA) was inserted into the inner tube wall to serve as the protein release 
point. The small conduit was placed inside the larger conduit with the space between the 
two serving as the drug reservoir for BSA (A8022-500G, Sigma Life Science, St. Louis, 
MO). The space between the tubes at the end was sealed with silicone sealant (RTV 734, 
2307774-1008, Dow Corning, Midland, MI) such that protein could only cross the filter 
membrane for release. A 7-day (171-hour) release and leakage test was performed in 
order to explore the capacity of this PLGA device to deliver protein. Samples included: 
30 µL of 300mg/mL (9 mg) BSA in PBS (n=2), negative controls (PBS alone) (n=2), a 
reference sample (to show the result if only 1.5% drug released) (n=1) and positive 
control with 42µL 300mg/mL BSA directly injected into the receiver chamber (n=1). A 
conduit that had no filter in place in the inner lumen was sealed at the ends to test the 
sealing of the device (leakage test) (n=2).  The devices were placed in glass vials filled 
with 7.5mL PBS as the release medium for the receiver chambers. 
Results and Discussion 
In the 171-hour period, 8.8 or 4.3mg BSA (~98% and 48%, respectively, of the 
total loaded dose) was released from the two test nerve conduits, as shown in Figure 37.  
The leakage test sample had near-zero BSA release in the 171 hour period supporting the 
idea that any BSA release observed from the test conduits were through the filter.  





Figure 37 Seven-day (171-hour) BSA release and leakage test of PLGA devices 
Conclusions 
This device has the ability to deliver protein in a sustained, controlled fashion.  
Thus, this device will be loaded with drugs such as nerve growth factor which can 
stimulate axon growth and assessed for efficacy for nerve regeneration in in vivo models. 
A 26-day NGF Study from PLGA Nerve Conduit 
Introduction 
Because the model was not available at the time when running this study, the 
purpose for this pilot 26-day NGF release study with PLGA nerve conduit is to determine 
the optimal combination of PVA and NGF for a later 26-day NGF study from PLGA 





Materials and Methods 
In order to verify the bioactivity of the NGF delivered from the PLGA nerve 
conduit in a 26-day period, DMEM with 10% FBS was chosen to be served as the media 
in the receiver chamber instead of PBS to allow future cell culture on chick DRG cells.  
The fabrication process and the test setup are the same as the ones shown in Chapter 3 
previously; only the dosage of NGF and PVA loaded into the device is different.  NGF 
was first dissolved in distilled water to form a drug initial of 0.1mg/mL NGF stock 
solution, as shown in Table 15.  Table 16 shows the dosage of drug filled into each 
control and device.  Drug 1 solution was prepared by mixing 200µL drug initial with 
200µL 50mg/mL PVA to form a final 0.05mg/mL NGF in 25mg/mL PVA solution.  
Drug 2 solution was prepared by mixing 50µL drug 1 solution with 200µL 25mg/mL 
PVA to form a final 0.01mg/mL NGF in 25mg/mL PVA solution.  Drug 3 was prepared 
by mixing 100µL drug 2 solution with 100µL 25mg/mL PVA to form a final 
0.005mg/mL NGF in 25mg/mL PVA solution.   















Drug initial 0.1mg/mL Initial Initial 700µL n/a n/a 










































Table 16 Dosage of drug filled in each control and device 
Device name Device Drug Receiver 
chamber 
Purpose 
Positive Control  
(PC) 
n/a 100µL drug 1 
(0.05mg/mL) 
10mL DMEM 
& 10% FBS 
To set the 
maximum 
boundary 
Leakage Test  
(LT) 
w/o window 22µL drug 1 
(0.05mg/mL) 
3mL DMEM & 
10% FBS 
To see the 
device’s ability 
to store NGF 
without leakage 
Device 1  
(D1) 
w/ window 18µL drug 1 
(0.05mg/mL) 





Device 2  
(D2) 
w/ window 24µL drug 2 
(0.01mg/mL) 




Device 3  
(D3) 
w/ window 28µL drug 3 
(0.005mg/mL) 




Blocking Test  
(BT) 
w/ window 12µL 
Unblocked drug 
(0.05mg/mL) 
3mL DMEM & 
10% FBS 







w/ window 30µL 25mg/mL 
PVA solution 
3mL DMEM & 
10% FBS 
To determine the 
background 
noise 
An “unblocked drug” was introduced into this study in order to compare the 
absence of PVA in the release kinetics, and this unblocked drug was prepared from 
mixing 100µL of drug initial with 100µL of distilled water to form a final 0.05mg/mL 
NGF solution.   
The positive control (n=2) is to set the maximum boundary for the NGF signal, and 
the negative control is to determine the background noise.  For the leakage test, the 
device with no diffusion window was used in order to verify the sealing of the PLGA 
device.  Three devices were used to compare the NGF delivery rate for different given 
NGF dosage (n=1).  A blocking test was added in order to verify if the absence of PVA 




Fifty µL of 0.05mg/mL NGF in 5mL DMEM with 10% FBS was used as the 
receiver chamber media for the positive controls, and 500µL solution was taken from 
each positive control without refilling fresh DMEM with 10% FBS solution back.  
Contrarily, 3mL DMEM with 10% FBS was used for all the device groups, leakage test 
and negative control.  Sink method was used in these groups in which all the media in the 
receiver chamber will be replaced each time during collection.  All media collected will 
be stored at -20ºC, and the ELISA will be taken at the same time after collecting all the 
data points.   
Results and Discussion 
Due to the space limitation on the NGF ELISA kit, only the first collection of the 
positive control was measured and a 25558pg/mL NGF concentration was measured.  
Because it already exceed the NGF ELISA’s detection range of 0.049ng/mL to 15ng/mL, 
these data are meaningless for this study.  In addition, the positive control is only to give 
the idea that the scenario if all NGF released into the receiver chamber between two 
collections, which is not the goal for the device.  In contrast, calibrated samples were 
proposed and tested in the release studies discussed in Chapters 3.  Signals of these 
calibrated samples fell into the ELISA region due to the better design of experiment.  
Release results are shown in Figure 38 and Figure 39.   
Figure 38 shows the cumulative NGF mass release into the receiver chamber.  
Device 1 filled with the highest dosage of NGF has the highest release, with an average 
of 3.4ng/day daily NGF delivery.  Due to some blockage of the filter on the device 2, a 
near-zero release was found in a 26-day period.  Device 3 has a moderate release due to 




that even without the presence of PVA, the NGF release is slower than the devices.  
Negative control fit the expectation to have a near-zero release in the 26-day period.  
Figure 39 shows the cumulative NGF release percentage in the 26-day period.  For 
the percentage of NGF released into the receiver chamber, both devices 1 and 3 have a 
cumulative release of less than 10%.  It indicates that a lesser concentration of PVA can 
be used in order to speed up the diffusion rate in the 26-day period.  Therefore, in the 25-
day NGF release study, PLGA devices will be filled with either 12.5mg/mL or 25mg/mL 
PVA and 0.05mg/mL or 0.1mg/mL NGF for a faster and higher NGF release.    
 
Figure 38 Cumulative NGF (in pg) release into the receiver chamber in a 25-day NGF 





Figure 39 Cumulative NGF (in percentage) release into the receiver chamber in a 25-day 






































A 3-week Pilot Animal Study in Rats 
Introduction 
The purpose for this pilot animal study is to verify the device with the same design 
of the optimal device in the 25-day NGF release study can promote axonal outgrowth 
along a given 10mm gap on rat sciatic nerve.  Previously experiment shows that the 
axonal regrowth rate of 1-4mm/day [56], so that this 3-week animal study will not be 
evaluated by electrophysiology or walking track analysis due to that the repaired axons 
are not fully extended to innervate the distal muscles, and in this case, gastrocnemius and 
soleus muscles.  Only histology and muscle loss data will be compared in this pilot 
animal study.   
Materials and Methods 
The optimal combination of NGF and PVA obtained from the 25-day diffusion test, 
which is 20-28µL of 0.1mg/mL NGF in 12.5mg/mL PVA, would be used for a 3-week 
animal study in rats in order to evaluate the outcome of the nerve conduit in vivo.  In this 
study, a 10mm gap in the left sciatic nerve would be created in two groups (n=4) of 6-
month-old female white Sprague Dawley rats.  Before the surgery, PLGA nerve conduits 
would be sterilized by STERRAD.  Then, in the biohood, the desired NGF and PVA 
would be filled into the device to avoid contamination.  PLGA nerve conduits with 
desired NGF and PVA combination would be implanted into one group (n=4) of rats, and 
PLGA nerve conduits with empty reservoirs would be implanted into another group (n=4) 
of rats.  After 3 weeks, the rats would be sacrificed, and both the histology of the left 
sciatic nerve gap with the PLGA nerve conduit and the muscle loss comparison of both 




Results and Discussion 
No excessive inflammatory response was observed after bridging the 10 mm gaps 
on the left sciatic nerve of all rats (2 groups, n=4).  One rat from the group with NGF 
supply was sacrificed before the proposed deadline because it consumed its left leg.  
Therefore, results for muscle loss in gastrocnemius and soleus muscles were obtained 
from the 7 remaining rats after a 3-week trial.  For both gastrocnemius and soleus 
muscles, Figure 40 shows the group with NGF supply has a lower muscle loss ratio 
compared to the group without NGF supply.  Figure 41 shows the gastrocnemius and 
soleus muscle loss in each animal model.   
Less muscle loss rate in both gastrocnemius and soleus muscles when supplying 
NGF indicates that the peripheral nerve regenerated faster and some peripheral nerves 
regenerate across the gap to innervate the muscles.  However, because a lower number of 
animals was used in this pilot animal study, a larger standard deviation value was 
acquired, as shown in Figure 41.  Also, at 3 weeks, most of the peripheral nerves cannot 
grow long enough to innervate the distal muscles.  Therefore, a longer experiment will be 
conducted in order to verify the muscle loss result appropriately.  Walking track analysis 
will also be conducted to verify the functional recovery of the injured peripheral nerves.   
Due to the complex structure of the PLGA device, histology data are difficult to 
obtain in the way to remain newly-growing neuron cells inside the inner conduit of the 
PLGA device.  No histology data are available at this point, and future PLGA device will 
be inserted with either a peripheral nerve or a rat tail into the inner conduit for practice 






Figure 40 Muscle loss comparison in rats after 3 week pilot animal study.  (a) 
Gastrocnemius muscle loss comparison for groups with and without NGF supply; (b) 





Figure 41 Comparison of muscle loss in each animal model (a) Gastrocnemius and (b) 
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Complete PLGA Device Preliminary Study 
Introduction 
Because the PDMS plug, PES filter membrane and RTV silicone sealant  are not 
biodegradable, a follow-up surgery is required to remove the PLGA device after the 
nerve gap was bridged at 3 to 6 months postimplantation.  This could injure the recovered 
peripheral nerve.  Thus, a PLGA device using only biodegradable material is proposed to 
eliminate the need for the second surgery.   
Materials and Methods 
Biodegradable materials with similar functions of the PDMS plug, PES filter 
membrane and RTV silicone sealant are proposed in this complete PLGA device study.  
No plug would be used in this complete PLGA device due to the fact that the plug will 
decrease the volume of the drug reservoir.  For replacing the PES filter membrane, a 
model, which was discussed initially in Chapter 2, will be used to design the 
corresponding small diffusion holes drilled on the inner conduit of the PLGA device, as 
shown in Figure 42.  Because this is the first time to drill holes using laser on the inner 
conduit, it is difficult to get a precise dimension of the holes, and the dimension of the 
holes ranges from 100µm to 300µm.  A modeling system for designing NGF release from 
this complete PLGA device will be discussed in the next section.  Contrarily, melted 
PLGA instead of RTV silicone sealant was used to seal the end of the inner and outer 
conduit.  75/25 PLGA was heated to 230ºC for 20 minutes on a hot plate (6796-620KIT, 
Corning), then a needle was used to apply the melted PLGA emulsion to seal the end of 
the complete PLGA device.  A nail clipper was then used to trim the PLGA sealant.   





Figure 42 Small diffusion holes drilled on the inner conduit of the complete PLGA device 
compared to a United States penny 
one, approximately 200µm, hole (with plus/minus 100µm) on the inner conduit would be 
used as the diffusion window for NGF to release into the receiver chamber.  Also, 
because the 1
st
 hour solution in the 25-day NGF release study impeded and killed most of 
the chick DRG cells in the bioactivity test, no RTV sealant would be used to either seal 
the end of the PLGA device or attach the PLGA to the bottom of the 12-well plate 
(serving as the diffusion chamber).  Uncured 10:1 PDMS would be used to attach the 
complete PLGA device to the 12-well plate.  In addition, due to the previous 




10% FBS as the media for the receiver chamber, Amphotericin B (50-0640, Gibco) 
would be added into the solution of DMEM with 10% FBS.   
After sterilizing PLGA devices completely with STERRAD, one group (n=3) of 
PLGA devices would be filled with 30-35µL 0.025mg/mL NGF without PVA in this 
PLGA device preliminary study.  No controls were involved in this preliminary study due 
to the purpose of this study is to verify the sterilization and the complete PLGA device.  
These devices were then sealed with melted 75/25 PLGA.  One hundred and fifty µL 
receiver chamber media (DMEM with 10% FBS and 1x Amphotericin B) would be used 
to flush the inner conduit in order to reduce trapped air in the inner conduit.  The device 
was then attached to the bottom of a 12-well plate by uncured PDMS, following by a 2-
hour drying process in the cell culture hood.  Then, 5mL of the receiver chamber media 
was filled into each well.  All the steps mentioned in this paragraph are taken in the cell 
culture hood to minimize the contamination.  The receiver chamber was placed in the 
37ºC incubator.  All the media in the receiver chamber will be replaced with fresh media 
each time during collection.  Samples would be collected every 2 to 3 days in a 20-day 
period.  Collected sample would be stored at -20ºC.   
Results and Discussion 
Because this is a preliminary study, no NGF ELISA reading was available.  
Contamination was found at the 20
th
 day, which indicates that a further investigation of 
the sterilization of the experiment environment has to be conducted prior to the next 





Modeling of NGF Release from Complete PLGA Devices 
Introduction 
There will be two models for predicting the release kinetics.  The first model is for 
predicting both the daily protein delivery rate across the diffusion hole and the local 
protein concentration before meeting the proximal nerve stump.  The second model is to 
predict the protein concentration in the receiver chamber when the sink method is used.  
In short, a drug delivery device has to first show that it can deliver the protein at the rate 
and concentration specified in the first model, then the second model will determine if 
this design can produce a detectable protein signal in the receiver chamber because each 
detection method has its detectable range.   
One of the purposes for the first model is to predict the daily NGF release and the 
NGF concentration in the receiver chamber.  Literature has shown that a 80ng/day daily 
NGF supply for 3 weeks has greater sensorimotor recovery compared to all other 
treatment groups [96].  Another study shows that 10ng/mL NGF will result in the longest 
axonal outgrowth when compared to the group treated with NGF from 0.01ng/mL to 
100ng/mL on chick DRG cells [93].  Though the optimal dosage of NGF differs from 
different animal model or implantation location, a modeling system was developed to 
achieve a 10ng/day NGF delivery because smaller animal models (rat, mouse and chick) 
were used in our release studies.   
Another purpose of the first model is to predict the local protein concentration right 
before exposing to the proximal nerve stump sutured in the inner conduit.  A study shows 
that an optimal axonal growth was found in the environment of 800pg/uL NGF [96], 




the proximal nerve stump to promote optimal axonal outgrowth.   
In contrast, the second model can predict the protein concentration in the receiver 
chamber when the sink method is used in which the media of the receiver chamber will 
be replaced each time during collection.  This model can ensure that the range is within 
the detectable range of the preferred detection method, no matter in ELISA, plate reading 
or other techniques.   
First Model: Local Protein Concentration and Daily Delivery Rate 
Figure 43 shows the illustration of the PLGA device and a simplified illustration of 
the complete PLGA device.  Four stages were assigned as the following: stage 0 as the 
donor chamber where the drug reservoir filled with desired protein; stage 1 as the area in 
the inner conduit near the diffusion hole; stage 2 as the area in the inner conduit at the 
boundary of the proximal nerve stump; and stage E as 1mm inside the proximal nerve 
stump where all the protein is “consumed” due to metabolism (or sink method in the 
diffusion study).   
Based on Fick’s First Law of Diffusion,  
    
     
  
 Equation 8 
where J is the diffusion flux (
  
   
 ; D is the diffusion coefficient  
  
 




  and Δx is the distance between two stages.  Given that the diffusion 
flux between stages 0-1, 1-2 and 2-E being J0-1, J1-2 and J2-E, respectively; the area for the 
diffusion filter, inner conduit transverse cross-sectional area, and proximal nerve stump 





Figure 43 Illustration of the first model to predict both the local protein concentration in 
the proximal nerve stump and the daily protein diffusion rate across a diffusion hole 
stages 0, 1, 2 and E being C0, C1, C2 and CE, respectively; the distance between stages 0-1, 
1-2 and 2-E being Δx0-1, Δx1-2 and Δx2-E, respectively; we can obtain three diffusion 
equations as:  
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 Equation 11 
Diffusion coefficient in the nerve stump is half of the one in the incompressed 
buffer shown in previous studies [141][142], and was used in Equation 4.   
Assume that the diffusion mass flow is the same in stages 0-1, 1-2 and 2-E, we will 
get:  
                           Equation 12 
Because a C2 value of 800ng/mL and a J0-1A0-1 value of 10ng/day are required, a 
starting donor chamber concentration of C0 and the diffusion hole size and number can be 











Table 17 Known parameters in the first model, for the rat and mouse complete PLGA 
device 





Inner conduit cross-sectional area  A1-2                     m
2
 
Cross-sectional area in the 
proximal nerve stump 
A2-E                  m
2
 
Inner conduit wall thickness Δx0-1 200 100 µm 
Distance between the diffusion 
hole to the proximal nerve stump 
Δx1-2 5 5 mm 
Assume the length of the proximal 
nerve stump in the inner conduit 
Δx2-E 1 1 mm 
Assume the protein concentration 
is zero in the given distance inside 
the proximal nerve stump 
CE 0 0 ng/m
L 
Diffusion coefficient D 0.00000126 [141] [142] cm
2
/s 
calculates in a gap of 1 minute in a 30-day period, and the protein released previously 
will be deducted from the donor chamber so that a slower and slower release will be 
expected.   
A PLGA device for rats will be designed first, in which an inner conduit with a 
2.4mm outer diameter and 2mm inner diameter will be used in order to fit a sciatic nerve 
with the diameter of 1.6mm.  After entering the parameters shown in Table 17, when 




delivery rate of 9.9ng/day with a 0.15ng/day standard deviation and a proximal nerve 
local NGF concentration of 908.8ng/mL with a 14.3ng/mL standard deviation will be 
acquired for the 30-day period.   
For the complete PLGA device implanted into mice, a smaller inner conduit with an 
outer diameter of 1.2mm and an inner diameter of 1mm will be used to fit a thinner 
sciatic nerve of the diameter of 0.9mm.  After entering the values, shown in Table 17, in 
the model, when filling the complete PLGA device with a donor chamber concentration 
of 0.05mg/mL and using three 25µm diffusion holes, an average of 6.8ng/day daily NGF 
delivery rate with a 0.1ng/day standard deviation and an average proximal nerve stump 
NGF concentration of 1977.9ng/mL with a 30.1ng/mL standard deviation will be 
obtained.  This model can show the diffusion kinetics and the local protein concentration 
of any PLGA nerve device for either rats or mice if dimensions of the devices are 
provided. 
Second Model: Protein Concentration in the Receiver Chamber 
The second model is to predict the protein concentration in the receiver chamber 
when the sink method is used.  Similar to the first model, a simplified system was used to 
calculate the protein concentration in the receiver chamber using Fick’s First Law of 
diffusion.  Figure 44 shows the concept of this model, in which a donor chamber (stage 0) 
filled with the desired protein will diffuse through diffusion holes and enter the inner 
conduit (stage 1).  The protein then diffuses from the inner conduit to the receiver 
chamber (stage 2).   
The calculation of drug and protein release is similar to the first model.  Two 





Figure 44 Illustration of the second model to predict the protein concentration in the 
receiver chamber 
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where J is the diffusion flux (
  
   
 ; D is the diffusion coefficient  
  
 




  and Δx is the distance between two stages.  Given that the diffusion 
flux between stages 0-1 and 1-2 being J0-1 and J1-2, respectively; the area for the diffusion 
filter and inner conduit transverse cross-sectional area being A0-1 and A1-2, respectively; 
the concentration at stages 0, 1 and 2 being C0, C1 and C2, respectively; the distance 
between stages 0-1 and 1-2 being Δx0-1 and Δx1-2, respectively; we can obtain three 
diffusion equations.   
Because the diffusion of the inner conduit to the receiver chamber is in two 
directions from the donor chamber,  
                     Equation 15 
Also, net protein increment (in mass) in the receiver chamber equals the net mass 










    
              
 
 Equation 16 
where t is the time (second) allowed for diffusion, and V is the volume (m
3
) in the 
receiver chamber.  
From these equations, we can get the concentration of the inner conduit (C1) as: 
   
                                     
                                               
 Equation 17 
Then, the concentration in the receiver chamber (C2) is:  
      
          
 
 Equation 18 
All calculation was conducted in Microsoft Excel, and after entering the parameters 
shown in Table 17 and described in the previous sections, the concentrations in the 












 day and 30
th
 day 
collection with the sink method used are shown in Table 18.   
Because the detection range of NGF ELISA is 0.049ng/mL to 15ng/mL, all the data 
points fit into this range.   
These two models will be used to design different complete PLGA devices filled 
with different protein to fit various applications.   
Table 18 The protein (NGF) concentration (ng/mL) in the receiver chamber for rat and 
















Rat 2.1 8.3 10.2 10.1 10.0 10.0 9.9 





Several tests related to the nerve conduit project were performed in addition to the 
ones presented in Chapters 3 and 4, in order to develop the device as well as 
methodologies for the nerve conduit project in Chapters 3 and 4.  These supporting tests 
are discussed in this chapter.   
A 5-day basic VEGF release study from PDMS nerve conduit is the first release 
experiment of the nerve conduit project, but the results cannot be interpreted due to the 
design error of the standard VEGF concentration calibration curve.  A 6-day BSA release 
study from PDMS nerve conduit shows that two out of three devices filled with the same 
amount of BSA have a similar release profile in the 6-day period.  Another PDMS device 
with different design using diffusion holes as the diffusion window was then performed 
with Dextran as the biomarker.  It showed a reasonable release from the devices, but the 
result of the control is not favorable due to the diffusion chamber setting, thus an 
improvement design, along with the previous success in 6-day BSA release from the 
PDMS device, were tested and discussed previously in Chapter 3.  After the success of 
NGF release data in Chapter 3, new material was proposed to better suit the clinical 
application.  PLGA was chosen, and its pilot study were performed in this chapter 
(Chapter 5) in which a 7-day BSA release study from PLGA nerve conduit shows two out 
of two devices can release BSA in a 7-day period.  A 26-day NGF study from PLGA 
nerve conduit was then performed in order to achieve an average of 2ng/day NGF 
delivery, with the comparison between different NGF and PVA concentration.  The 
optimal design consisting of 0.05mg/mL NGF in 50mg/mL PVA has 3.4ng/day average 




protocol used in Chapter 4, in which PLGA devices with various NGF and PVA 
concentration were used to achieve 2ng/day daily NGF release.  In addition, two models 
were developed in order to predict the release kinetics of either the PLGA or the PDMS 
device, and these models were introduced and discussed in both Chapters 3 and 5.   
 CHAPTER 6 
CONCLUSION 
This dissertation consists of two medical device projects: intraocular pressure 
sensors and nerve conduits.  The author will conclude the findings for the former project 
first, followed by a thorough explanation of the later project.  The author’s contribution 
will also be addressed in this chapter, followed by the future work proposed for the two 
medical device projects.   
Intraocular Pressure Sensors 
Two types of IOP sensors have been designed, fabricated and tested.  The 
subconjunctival IOP sensors possess a more feasible application compared to the 
intracapsular IOP sensors because of the easiness for both implantation and signal 
detection.  The PMMA intracapsular IOP sensors have a drawback of the immobility of 
the dye in the channel, resulting in a huge hysteresis when IOP value drops.  Also, 
silicone to PMMA bonding cannot be controlled easily when compared to PDMS to 
PDMS bonding; so a leakage in the channel is more likely to occur, leading to failure of 
the device.   
Subconjunctival IOP sensors made of PDMS were found to be superior when 
compared to the intracapsular IOP sensors made of PMMA.  Seven out of 70 tested 
subconjunctival IOP sensors show the ability to detect both rising and falling IOP 
pressures, with the signal being retrievable with OCT when covered with swine 




devices should be performed to acquire more data for the average dye length calibration 
curves in order to get a more precise prediction of intraocular pressure based on the dye 
length measurement.   
Nerve Conduits for Peripheral Nerve Regeneration 
The nerve conduit project started with a concept that concentric tubes storing drugs 
of interest in the lumen between the two tubes will slowly release the drug into the lumen 
of the inner lumen and promote local axonal outgrowth at the proximal nerve stump 
sutured in the inner conduit.  In the beginning, a PDMS device with a PCU inner conduit 
was used to deliver BSA or VEGF through a PES filter membrane.  Then, NGF was 
loaded into this PDMS device for a more directly applicable study and the results showed 
that all three PDMS devices had different release kinetics in which one PDMS device 
released nothing, another slowly released NGF, and the other released NGF rapidly in the 
first 37 hours and nearly nothing for the rest of the 21-day period.  Thus, the PDMS 
devices using the PES filter as the diffusion window had the drawback of inconsistent 
release kinetics in the same design due to either the application of adhesive on the filter 
that partially or totally blocks the diffusion window or possibly bubbles forming on the 
membrane.  Another explanation for the poor measurement results might be that the 
protein adheres to the glass wall after release and is not available to be measured, causing 
artificially low concentration measurements to occur.  Because of these challenges, a 
different device was designed and different measurement conditions implemented.   
Biodegradable PLGA nerve conduits were then developed in this project to 
hopefully eliminate the need for followup surgery to remove the conduit and to speed up 




achieved in a 7-day study.  A 26-day NGF release study using DMEM instead of PBS in 
the receiver chamber suffered from contamination and some tests had to be stopped in the 
middle of the 26-day period.  A more careful 25-day NGF release study with a higher 
dosage of NGF in order to acquire higher NGF concentration in the receiver chamber was 
performed and showed more consistent release kinetics than in the previous PLGA device 
release study, and the NGF released from the PLGA device was shown to be bioactive 
even after being stored in the PLGA device for 20 days, which was verified with DRG 
cells.  A pilot 3-week animal study in rats was conducted and showed that the device was 
generally biocompatible in vivo.  The optimal design was then used in a 3-week in vivo 
animal study in rats that again showed good biocompatibility, but was not long enough to 
show any significant difference in muscle loss protection from nerve regrowth.   
The PDMS and PLGA devices using filter membranes to release protein showed 
poor consistency in release results due to the possible blockage of filter membranes by 
the application of the adhesive.  A model using Fick’s First Law of Diffusion was 
proposed in Chapter 3, and 75 % of the PDMS devices with diffusion holes fit the 
modeling results in Dextran release percentage in a 10-day study.  This not only indicates 
that using diffusion holes instead of filter membranes can result in a more consistent 
release, but also validates that the model is useful for predicting the release kinetics of the 
device.   
Contribution 
The author made the following contributions to the IOP sensor project: 





 Modified the intracapsular IOP sensor. 
 Developed the subconjunctival IOP sensor. 
 Developed a PDMS partially cured bonding method for 20µm PDMS 
membrane attachement.  
 Tested and characterized 60 intracapsular IOP sensors and 70 
subconjunctival IOP sensors.   
 Introduced reservoirs for storing trapped air.   
 Introduced a protective layer for minimizing applied pressure on the sensing 
channel.  
 Published one conference paper: MicroTAS 2012 poster. 
 Journal paper ready for submission  
The author contributed the following items to the nerve conduit project: 
 Helped acquire the initial funding (University of Utah Research Foundation 
Seed Grant): $32k for 1 year. 
 Helped acquire more funding for expanding the study:  
o Department of Defense (DOD) Congressionally Directed Medical 
Research Program (CDMRP): $186k for 1.5 years. 
o DOD CDMRP: $744k for 3 years. 
 Developed the whole process from design, manufacture and verification the 
drug released in vitro.  
 Developed the PDMS device. 
 Developed the PLGA device. 




 Proposed using holes instead of using a filter.  Conducted preliminary 
fabrication using the laser etching machine.  
 Proposed several PLGA sealing methods, including PLGA glue and heat 
sealing. 
 Invented the PLGA outer conduit manufacturing process. 
 Developed the diffusion chamber for PLGA device release studies. 
 Invented methods for making PLGA sheets and PLGA disks for use in the 
device manufacture. 
 Developed modeling systems to predict: 
o Drug release kinetics from the donor chamber to the receiver 
chamber. (Detectability) 
o Drug release kinetics from the donor chamber to the proximal nerve 
stump. (Dosage)  
 Published 3 conference papers: 
o IEEE EMBC 2012 
o BMES 2013 
o ACS-Utah 2013 
 Two journal papers ready for submission 
Future work 
Intraocular Pressure Sensors 
In order to achieve better signal consistency, more results matching the error zone 
of the average dye length calibration curve should be acquired in order to get a precise 




conjunctiva should be harvested and placed on top of the subconjunctival IOP sensor to 
see if a better OCT signal could be achieved.  Furthermore, hysteresis in the 
subconjunctival sensors should be solved in order to get a repeatable signal reading.   
Nerve Conduits for Peripheral Nerve Regeneration 
A procedure for turning the design concepts into prototypes is proposed in order to 
accelerate the development process of the nerve conduits in the future.  This procedure 
includes the following steps: 
1. Obtaining the clinical needs in material, dimension and drugs of interest. 
2. Acquiring the dimension of the diffusion holes and the dosage of the drug 
filled in the drug reservoir by performing design characterization using the 
first model (proposed in Chapter 5) to verify if the drug delivery dosage to 
the proximal nerve stump meets expectations.   
3. Ensuring the dimension of the diffusion holes and the dosage of the drug 
filled in the drug reservoir is detectable by perform design characterization 
using the second model introduced in both Chapters 3 and 5.   
4. Fabricating the device with dimension obtained from the two models.   
5. Testing the integrity of the device in a sealing test using Dextran with a 
similar molecular weight to the drug of interest.   
6. Testing the consistency of the drug release kinetics in a 30-day release study 
using Dextran with a similar molecular weight to the drug of interest.   
7. Practicing the histology techniques for the proposed device with a biological 
tissue inserted into the device.    




using the drug of interest.   
9. Verifying the bioactivity of the collected sample in the 30-day release study 
on DRG cells.   
10. Verifying the function of the device in a 1-month pilot animal study.   
11. Verifying the function of the device in a 6-month full animal study.   
Following these procedures, a complete PLGA device will be fabricated, and a 
dual-chambered device will also be developed to deliver multiple neurotrophins at once 
in order to fit different applications.  These PLGA devices will be designed using the 
modeling results in order to acquire an optimal delivery and release kinetics to not only 
be bioactive and detective but also be clinically preferred.  A diffusion test with the sink 
method will be started to verify the integrity and release kinetics of the complete PLGA 
device (single or dual chambers); then, an ex vivo study in DRG cells will be conducted 
to verify the bioactivity of the neurotriphin released from the devices.  If both the release 
kinetics and the bioactivity have been confirmed, a pilot 30-day in vivo test will be 
conducted in rats, followed by a 6-month full animal test in mice in order to inspect the 
electrophysiology, histomorphometry and walking track analysis data compared to the 
group bridged with autografts.  
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